id,evidence_inference_prompt_id,pmcid,outcome,intervention,comparator,outcome_type,intervention_events,intervention_group_size,comparator_events,comparator_group_size,intervention_mean,intervention_standard_deviation,comparator_mean,comparator_standard_deviation,notes,is_data_in_figure_graphics,is_relevant_data_in_table,is_table_in_graphic_format,is_data_complete,tiktoken_with_attributes_xml_token_num,tiktoken_without_attributes_xml_token_num,tiktoken_without_attributes_markdown_token_num,split
1,11248,57750,Death or myocardial infarction,eptifibatide,placebo,binary,,,,,,,,,Group sizes are not given so the events cannot calculate using the percentages.,FALSE,FALSE,FALSE,FALSE,5811,4777,3265,DEV
2,11249,57750,Myocardial infarction,eptifibatide,placebo,binary,,,,,,,,,Group sizes are not given so the events cannot calculate using the percentages.,FALSE,FALSE,FALSE,FALSE,5811,4777,3265,DEV
3,11266,1216327,The mean body weight gain,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30,,30,50.6,,-0.7,,Missing standard deviations,FALSE,TRUE,FALSE,FALSE,6350,5198,3913,DEV
4,11267,1216327,The duration of the illness,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30,,30,47.5,38.9,26.5,27.4,,FALSE,TRUE,FALSE,TRUE,6350,5198,3913,DEV
5,11268,1216327,The fecal losses,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30,,30,3.59,2.35,2.19,1.63,,FALSE,TRUE,FALSE,TRUE,6350,5198,3913,DEV
6,11451,1574360,The amount of saturated fat in the foods purchased,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,continuous,,251,,246,0.77,1.37,0.04,0.32,Have to use CI to calculate the SDs,FALSE,FALSE,TRUE,TRUE,1959,1620,1376,TEST
7,11452,1574360,the average cost of the food,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,continuous,,251,,246,0.63,0.4,0.62,0.36,Have to use CI to calculate the SDs,FALSE,FALSE,TRUE,TRUE,1959,1620,1376,TEST
8,9683,2363753,Days with fever,Amifostine,Control,continuous,,20,,20,,,,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,FALSE,887,780,725,TEST
9,9684,2363753,Hospital stay,Amifostine,Control,continuous,,20,,20,,,,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,FALSE,887,780,725,TEST
10,9682,2363753,Grade III/IV stomatitis,Amifostine,Control,binary,0,20,5,20,,,,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,TRUE,887,780,725,TEST
11,9681,2363753,Glomerular filtration rate fall,Amifostine,Control,continuous,,20,,20,10,,37,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,FALSE,887,780,725,TEST
12,12632,2667135,number of days with received courses of antibiotics,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,continuous,,103,,97,25.4,23.34,13.5,9.49,,FALSE,FALSE,FALSE,TRUE,11722,8106,5529,TEST
13,12633,2667135,proportion of patients completed therapy,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,93,103,44,97,,,,,,FALSE,TRUE,FALSE,TRUE,11722,8106,5529,TEST
14,12634,2667135,early discontinuations,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,10,103,54,97,,,,,,FALSE,TRUE,FALSE,TRUE,11722,8106,5529,TEST
15,12635,2667135,rate of clinical success at the test-of-cure visit,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,89,103,54,97,,,,,,FALSE,TRUE,FALSE,TRUE,11722,8106,5529,TEST
16,12636,2667135,deaths,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,4,103,18,97,,,,,,FALSE,TRUE,FALSE,TRUE,11722,8106,5529,TEST
17,8237,2681019,Adiponectin in women,Red wine,Control,continuous,,,,,,,,,Mean and SD in figure. Group sizes not available in results section.,TRUE,FALSE,FALSE,FALSE,726,647,543,DEV
18,8238,2681019,Adiponectin in men,Ethanol solution,Control,continuous,,,,,,,,,Mean and SD in figure. Group sizes not available in results section.,TRUE,FALSE,FALSE,FALSE,726,647,543,DEV
19,8239,2681019,Adiponectin in men,Beer,Control,continuous,,,,,,,,,Mean and SD in figure. Group sizes not available in results section.,TRUE,FALSE,FALSE,FALSE,726,647,543,DEV
20,3246,2972614,Adverse effects,Laser therapy (Group I),Placebo laser therapy (Group II),binary,0,30,0,22,,,,,,FALSE,FALSE,FALSE,TRUE,7041,2968,1931,TEST
21,3243,2972614,Severity of pain,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,3.76,1.45,4.63,2.1,,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
22,3245,2972614,Shoulder Pain and Disability Index score,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,48.13,22.1,40.99,20.98,,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
23,3247,2972614,Laboratory parameters,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,,,,,Unclear outcome and also no numerical data for this specific outcome,FALSE,FALSE,FALSE,FALSE,7041,2968,1931,TEST
24,3244,2972614,Motion range - Shoulder flexion,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,168,22.65,174.31,14.98,Outcome originally just Motion range.,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
25,3244,2972614,Motion range - Shoulder extension,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,42.66,3.4,42.95,3.98,Outcome originally just Motion range.,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
26,3244,2972614,Motion range - Shoulder abduction,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,166.66,21.38,172.72,16.67,Outcome originally just Motion range.,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
27,3244,2972614,Motion range - Shoulder adduction,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,42,4.27,42.04,5.26,Outcome originally just Motion range.,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
28,3244,2972614,Motion range - Shoulder internal rotation,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,49.33,9.62,49.77,4.49,Outcome originally just Motion range.,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
29,3244,2972614,Motion range - Shoulder external rotation,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30,,22,44.83,5.64,44.09,1.97,Outcome originally just Motion range.,FALSE,TRUE,FALSE,TRUE,7041,2968,1931,TEST
30,5576,3003523,Short-Form 36-Items improvement,Certolizumab 200 mg,Control,continuous,,393,,199,38.1,9.5,31.5,7.4,Used values for PCS after 52 weeks (final timepoint).,FALSE,TRUE,FALSE,TRUE,12247,10091,7520,TEST
31,5577,3003523,Short-Form 36-Items improvement,Certolizumab 400 mg,Control,continuous,,390,,199,38.9,8.9,31.5,7.4,Used values for PCS after 52 weeks (final timepoint).,FALSE,TRUE,FALSE,TRUE,12247,10091,7520,TEST
32,5580,3003523,Pain,Certolizumab 400 mg,Control,continuous,,390,,199,53.9,22.2,34,20.1,Used values for weeks 52 (final timepoint).,FALSE,TRUE,FALSE,TRUE,12247,10091,7520,TEST
33,5575,3003523,Health-related quality of life improvement - Short-Form 36-Items improvement,Certolizumab 200 mg,Control,continuous,,393,,199,38.1,9.5,31.5,7.4,This outcome is measured by Short-Form 36-Items (SF-36).,FALSE,FALSE,FALSE,TRUE,12247,10091,7520,TEST
34,5578,3003523,Mental Component Summary improvement,Certolizumab 400 mg,Control,continuous,,390,,199,45.4,11.5,41.1,10.8,Used values for MCS after 52 weeks (final timepoint).,FALSE,TRUE,FALSE,TRUE,12247,10091,7520,TEST
35,5579,3003523,Fatigue Assessment Scale improvement,Certolizumab 200 mg,Control,continuous,,393,,199,,,,,Values are in figure.,TRUE,FALSE,FALSE,FALSE,12247,10091,7520,TEST
36,6988,3169777,adverse event profile - headache,macitentan dose of 600 mg,placebo,binary,5,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
37,6985,3169777,unexpected adverse events,macitentan doses of 0.2 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
38,6985,3169777,unexpected adverse events,macitentan doses of 1 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
39,6985,3169777,unexpected adverse events,macitentan doses of 5 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
40,6985,3169777,unexpected adverse events,macitentan doses of 25 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
41,6985,3169777,unexpected adverse events,macitentan doses of 100 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
42,6985,3169777,unexpected adverse events,macitentan doses of 300 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
43,6985,3169777,unexpected adverse events,macitentan doses of 600 mg,placebo,binary,0,6,0,14,,,,,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,5143,4376,3326,TEST
44,6986,3169777,Plasma endothelin-1 concentrations,macitentan dose of 600 mg,placebo,continuous,,6,,14,,,,,The mean and SD are in bar chart (figure),TRUE,FALSE,FALSE,FALSE,5143,4376,3326,TEST
45,6989,3169777,adverse event profile - headache,macitentan doses of 0.2 mg,placebo,binary,0,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
46,6989,3169777,adverse event profile - headache,macitentan doses of 1 mg,placebo,binary,0,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
47,6989,3169777,adverse event profile - headache,macitentan doses of 5 mg,placebo,binary,0,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
48,6989,3169777,adverse event profile - headache,macitentan doses of 25 mg,placebo,binary,2,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
49,6989,3169777,adverse event profile - headache,macitentan doses of 100 mg,placebo,binary,1,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
50,6989,3169777,adverse event profile - headache,macitentan doses of 300 mg,placebo,binary,2,6,3,14,,,,,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,5143,4376,3326,TEST
51,5308,3195393,Continuous restraint,After restraint reduction program,Before restraint reduction program,continuous,,562,,463,8.5,0.07,10.8,0.13,Overall continuous restraint rate for study site.,FALSE,TRUE,FALSE,TRUE,15527,8380,5589,TEST
52,5306,3195393,Restraint frecuency,After restraint reduction program,Before restraint reduction program,continuous,,562,,463,13.6,0.07,11.5,0.13,Added intermittent and continuous numbers from study site,FALSE,TRUE,FALSE,TRUE,15527,8380,5589,TEST
53,5307,3195393,Intermittent restraint,After restraint reduction program,Before restraint reduction program,continuous,,562,,463,5.1,0.07,0.7,0.02,Overall intermittent restraint rate for study site.,FALSE,TRUE,FALSE,TRUE,15527,8380,5589,TEST
54,5309,3195393,Restraint knowledge,After restraint reduction program,Before restraint reduction program,continuous,,562,,463,6.23,,5.51,,No SD information provided,FALSE,FALSE,FALSE,FALSE,15527,8380,5589,TEST
55,10673,3276927,relieving factors in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19,,19,,,,,Data found in table in graphic format.,FALSE,TRUE,TRUE,FALSE,2011,1731,1429,DEV
56,10676,3276927,effective in the treatment of reversible inguinal hernia,post-Yoga,pre-Yoga,binary,,19,,19,,,,,"No real numerical data attached to this specific outcome. Other prompts account for ""treatment""",FALSE,FALSE,TRUE,FALSE,2011,1731,1429,DEV
57,10672,3276927,frequency of occurrence in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19,,19,,,,,Only median and range is given.,FALSE,TRUE,TRUE,FALSE,2011,1731,1429,DEV
58,10671,3276927,"symptoms of hernia such as heaviness, fullness and pain",post-Yoga,pre-Yoga,continuous,,19,,19,,,,,No specific numerical data associated with these symptoms.,FALSE,FALSE,TRUE,FALSE,2011,1731,1429,DEV
59,10674,3276927,pain in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19,,19,,,,,Only median and range is given.,FALSE,TRUE,TRUE,FALSE,2011,1731,1429,DEV
60,10675,3276927,aggravating factors in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19,,19,,,,,Only median and range is given.,FALSE,TRUE,TRUE,FALSE,2011,1731,1429,DEV
61,1642,3309311,differences in the disc herniation,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,20,23,6,19,,,,,Used percentage to calculate events as binary outcome.,FALSE,TRUE,TRUE,TRUE,1437,1263,1073,TEST
62,1642,3309311,differences in the LDD,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,23,23,9,19,,,,,Used percentage to calculate events as binary outcome. Outcome original HDD but changed to LDD to fix typo,FALSE,TRUE,TRUE,TRUE,1437,1263,1073,TEST
63,1642,3309311,differences in the annulus tear,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,23,23,5,19,,,,,Used percentage to calculate events as binary outcome.,FALSE,TRUE,TRUE,TRUE,1437,1263,1073,TEST
64,1642,3309311,differences in the HIZ,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,14,23,4,19,,,,,Used percentage to calculate events as binary outcome.,FALSE,TRUE,TRUE,TRUE,1437,1263,1073,TEST
65,1644,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)",adults with LBP with radicular pain (group C),binary,14,23,3,18,,,,,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,1437,1263,1073,TEST
66,1643,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,14,23,4,19,,,,,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,1437,1263,1073,TEST
67,3041,3321528,wrist flexion,electrical muscle stimulation (EMS),control,continuous,,24,,28,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,6725,3999,2880,TEST
68,3041,3321528,hip flexion,electrical muscle stimulation (EMS),control,continuous,,24,,28,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,6725,3999,2880,TEST
69,3041,3321528,knee extension,electrical muscle stimulation (EMS),control,continuous,,24,,28,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,6725,3999,2880,TEST
70,3041,3321528,ankle dorsiflexion,electrical muscle stimulation (EMS),control,continuous,,24,,28,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,6725,3999,2880,TEST
71,3043,3321528,handgrip strength,Intensive Care Unit acquired weakness (ICU-AW),without an ICU-AW diagnosis,continuous,,,,,6.6,4.4,23.4,8.9,Does not have group size information in article.,FALSE,FALSE,FALSE,FALSE,6725,3999,2880,TEST
72,3042,3321528,the total MRC score of the legs,electrical muscle stimulation (EMS),control,continuous,,24,,28,,,,,Only median and interquartile range is given.,FALSE,FALSE,FALSE,FALSE,6725,3999,2880,TEST
73,3741,3546023,Urine cotinine levels,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30,,19,1.179,0.738,0.047,0.017,Values are for week 24 (only timepoint after intervention).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
74,3742,3546023,serum α1-antitrypsin,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30,,19,1.75,0.39,1.45,0.24,Values are for week 24 (only timepoint after intervention).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
75,3743,3546023,The percentage of B cells,200 mg/day palmvitee nonsmokers,baseline,continuous,,29,,29,11.97,4,13.72,4.53,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
76,3744,3546023,The percentage of B cells,200 mg/day palmvitee smokers,baseline,continuous,,30,,30,14.06,3.81,14.4,4.03,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
77,3746,3546023,The percentage of NK cells,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30,,29,19.03,7.82,24.72,8.78,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
78,3740,3546023,tocopherol levels,200 mg/day palmvitee smokers,baseline,continuous,,30,,30,14.11,3.89,11.39,3.06,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
79,3740,3546023,tocotrienol levels,200 mg/day palmvitee smokers,baseline,continuous,,30,,30,587.68,87.5,59.49,4.21,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
80,3740,3546023,tocopherol levels,200 mg/day palmvitee nonsmokers,baseline,continuous,,29,,29,14.56,3.06,11.75,2.27,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
81,3740,3546023,tocotrienol levels,200 mg/day palmvitee nonsmokers,baseline,continuous,,29,,29,675.16,150,63.6,5.67,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
82,3745,3546023,CD4+/CD8+ ratio,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30,,29,1.19,0.43,1.03,0.53,Values are for week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,29733,18035,11524,TEST
83,11789,3580751,mean ± SD length of hospital stay between periods 1 and 2 in patients who did not suffer from VAP,Interrupted surveillance unit A,"Continuous surveillance, unit B",continuous,,940,,1831,9.9,14.8,9.1,9.9,Values are from post-intervention.,FALSE,FALSE,FALSE,TRUE,5335,4760,3573,DEV
84,13566,3687098,adverse event of constipation,sitagliptin 100 mg/day,comparator agent,binary,178,7726,124,6885,,,,,Used incidence rate per 100 to get the binary events.,FALSE,TRUE,FALSE,TRUE,15196,10904,8432,TEST
85,13567,3687098,The incidence rates of malignancy,sitagliptin 100 mg/day,comparator agent,binary,6953,7726,6403,6885,,,,,Used incidence rate per 100 to get the binary events.,FALSE,FALSE,FALSE,TRUE,15196,10904,8432,TEST
86,13568,3687098,The incidence rates of pancreatitis,sitagliptin 100 mg/day,comparator agent,binary,773,7726,689,6885,,,,,Used incidence rate per 100 to get the binary events.,FALSE,TRUE,FALSE,TRUE,15196,10904,8432,TEST
87,13569,3687098,The incidence of the composite endpoint of rash,sitagliptin 100 mg/day,comparator agent,binary,131,7726,76,6885,,,,,Used incidence rate per 100 to get the binary events.,FALSE,TRUE,FALSE,TRUE,15196,10904,8432,TEST
88,13244,3751573,improvement in nursing,phase I externship program,phase II corporate-academic cooperation program,continuous,,19,,23,117.63,19.01,158.52,23.19,Used post-intervention values.,FALSE,TRUE,FALSE,TRUE,8149,5521,3635,DEV
89,5538,3912320,Correct response rate for 500 Hz frequency,Occupational noise,Control,continuous,,19,,10,,,,,Mean were in a figure and SD was not given anywhere.,TRUE,FALSE,FALSE,FALSE,1648,1217,1015,TEST
90,5540,3912320,"Correct response rate for 4,000 Hz frequency",Occupational noise,Control,continuous,,19,,10,,,,,Mean were in a figure and SD was not given anywhere.,TRUE,FALSE,FALSE,FALSE,1648,1217,1015,TEST
91,5539,3912320,"Correct response rate for 2,000 Hz frequency",Occupational noise,Control,continuous,,19,,10,,,,,Mean were in a figure and SD was not given anywhere.,TRUE,FALSE,FALSE,FALSE,1648,1217,1015,TEST
92,10164,4173437,Postoperatively hematocrit,Tranexamic acid,Control,continuous,,30,,30,,,,,Had to infer that the group sizes were equal. Data is in table in graphic format.,FALSE,TRUE,TRUE,FALSE,854,745,637,TEST
93,10166,4173437,Complications,Tranexamic acid,Control,binary,0,30,0,30,,,,,Had to infer that the group sizes were equal.,FALSE,FALSE,TRUE,TRUE,854,745,637,TEST
94,10167,4173437,Adverse effects,Tranexamic acid,Control,binary,0,30,0,30,,,,,Had to infer that the group sizes were equal.,FALSE,FALSE,TRUE,TRUE,854,745,637,TEST
95,10163,4173437,Total blood loss,Tranexamic acid,Control,continuous,,30,,30,576,53,823,74,Had to infer that the group sizes were equal.,FALSE,FALSE,TRUE,TRUE,854,745,637,TEST
96,10165,4173437,Coagulation profile,Tranexamic acid,Control,continuous,,30,,30,,,,,Had to infer that the group sizes were equal. Data is in table in graphic format.,FALSE,TRUE,TRUE,FALSE,854,745,637,TEST
97,10168,4173437,Crystalloid solution needed,Tranexamic acid,Control,continuous,,30,,30,,,,,Had to infer that the group sizes were equal. No numerical values associated with this outcome.,FALSE,FALSE,TRUE,FALSE,854,745,637,TEST
98,931,4183415,completion of each dose at the correct time,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,continuous,,40,,37,33.1,21.6,32.6,18.4,Data found in Table 6.,FALSE,TRUE,FALSE,TRUE,10420,7106,5310,TEST
99,929,4183415,patient adherence,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,continuous,,40,,37,68.3,23.4,69.8,20.9,"Data found in Table 6. Used same values as ""completed treatment""",FALSE,TRUE,FALSE,TRUE,10420,7106,5310,TEST
100,930,4183415,Completed treatment,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,continuous,,40,,37,68.3,23.4,69.8,20.9,Data found in Table 6.,FALSE,TRUE,FALSE,TRUE,10420,7106,5310,TEST
101,1886,4188762,heart rate,remifentanil,normal saline,continuous,,30,,30,,,,,,TRUE,FALSE,TRUE,FALSE,2068,1758,1564,TEST
102,1886,4188762,heart rate,remifentanil,lidocaine,continuous,,30,,30,,,,,,TRUE,FALSE,TRUE,FALSE,2068,1758,1564,TEST
103,1886,4188762,heart rate,remifentanil,ketamine,continuous,,30,,30,,,,,,TRUE,FALSE,TRUE,FALSE,2068,1758,1564,TEST
104,1885,4188762,mean blood pressure,remifentanil,normal saline,continuous,,30,,30,,,,,,TRUE,FALSE,TRUE,FALSE,2068,1758,1564,TEST
105,1885,4188762,mean blood pressure,remifentanil,lidocaine,continuous,,30,,30,,,,,,TRUE,FALSE,TRUE,FALSE,2068,1758,1564,TEST
106,1885,4188762,mean blood pressure,remifentanil,"normal saline, lidocaine, or ketamine",continuous,,30,,30,,,,,,TRUE,FALSE,TRUE,FALSE,2068,1758,1564,TEST
107,1884,4188762,withdrawal response of rocuronium,lidocaine,normal saline,binary,6,30,26,30,,,,,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,2068,1758,1564,TEST
108,1884,4188762,withdrawal response of rocuronium,ketamine,normal saline,binary,9,30,26,30,,,,,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,2068,1758,1564,TEST
109,1884,4188762,withdrawal response of rocuronium,remifentanil,normal saline,binary,0,30,26,30,,,,,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,2068,1758,1564,TEST
110,9521,4319071,High-energy snack intake,Individual cognition and self-regulation processes intervention,Control,continuous,,459,,434,2.5,2.79,2.84,2.71,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,26475,16822,9628,TEST
111,9522,4319071,High-energy snack intake,Intervention + targeting environmental-level factors,Control,continuous,,456,,434,2.5,2.76,2.84,2.71,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,26475,16822,9628,TEST
112,9525,4319071,Vegetable intake,Intervention + targeting environmental-level factors,Control,continuous,,456,,434,167.61,83.71,158.67,78.33,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,26475,16822,9628,TEST
113,9526,4319071,Vegetable intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,continuous,,456,,459,167.61,83.71,173.28,81.63,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,26475,16822,9628,TEST
114,9523,4319071,Fruit intake,Intervention + targeting environmental-level factors,Control,continuous,,456,,434,2.17,1.71,2,1.67,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,26475,16822,9628,TEST
115,9524,4319071,Fruit intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,continuous,,456,,459,2.17,1.71,2.14,1.71,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,26475,16822,9628,TEST
116,2982,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,Mild-cooling,continuous,,9,,10,,,70,,,FALSE,TRUE,TRUE,FALSE,3049,2670,2328,TEST
117,2983,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,No cooling,continuous,,9,,13,,,15.4,,,FALSE,TRUE,TRUE,FALSE,3049,2670,2328,TEST
118,2984,4323894,Rate of complications,Mild-cooling or deep-cooling,No cooling,binary,,10,,13,,,,,,FALSE,TRUE,TRUE,FALSE,3049,2670,2328,TEST
119,2981,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Mild-cooling,No cooling,continuous,,10,,13,70,,15.4,,,FALSE,TRUE,TRUE,FALSE,3049,2670,2328,TEST
120,3102,4450164,ureteropelvic junction obstruction,internal drainage group,stentless cases,binary,8,20,13,44,,,,,,FALSE,TRUE,FALSE,TRUE,3862,2242,1567,DEV
121,7938,4486927,"The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype",peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,17,23,2,24,,,,,"Even though the outcome says rate, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,TRUE,FALSE,TRUE,14472,7883,5770,TEST
122,7936,4486927,The early virologic response (EVR),peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,86,94,82,93,,,,,,FALSE,TRUE,FALSE,TRUE,14472,7883,5770,TEST
123,7936,4486927,the end-of-treatment virologic response,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,83,94,75,93,,,,,,FALSE,TRUE,FALSE,TRUE,14472,7883,5770,TEST
124,7937,4486927,The SVR rates when the patients had BMI >30 kg/m2,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,10,19,6,12,,,,,"Even though the outcome says rate, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,TRUE,FALSE,TRUE,14472,7883,5770,TEST
125,4926,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H0 (saline),continuous,,50,,50,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,3932,3205,2434,TEST
126,4926,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H1(haloperidol 1 mg),continuous,,50,,49,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,3932,3205,2434,TEST
127,4924,4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H0 (saline),binary,11,49,21,50,,,,,Used numbers from Late time (2–24 h),FALSE,TRUE,FALSE,TRUE,3932,3205,2434,TEST
128,4924,4493951,the incidence of postoperative nausea and vomiting (PONV),H2 (haloperidol 2 mg),H0 (saline),binary,10,50,21,50,,,,,Used numbers from Late time (2–24 h),FALSE,TRUE,FALSE,TRUE,3932,3205,2434,TEST
129,4927,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,H0 (saline),"H1(haloperidol 1 mg),",continuous,,50,,49,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,3932,3205,2434,TEST
130,4925,4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H2 (haloperidol 2 mg),binary,11,49,10,50,,,,,Used numbers from Late time (2–24 h),FALSE,TRUE,FALSE,TRUE,3932,3205,2434,TEST
131,2451,4574984,numbers overall complications,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,238,326,241,326,,,,,,FALSE,TRUE,FALSE,TRUE,12997,7944,5795,TEST
132,2452,4574984,level of postoperative pain,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,234,326,261,326,,,,,,FALSE,TRUE,FALSE,TRUE,12997,7944,5795,TEST
133,2453,4574984,overall mortality,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,45,326,58,326,,,,,Used numbers from 1 year after surgery (final timepoint) to get the full scope since the outcome is OVERALL mortality. This info is found in Figure 6 caption.,FALSE,FALSE,FALSE,TRUE,12997,7944,5795,TEST
134,2449,4574984,Health-Related Quality of Life at 12 month - females,"intervention group, i.e. patient empowerment through information booklet and diary keeping - females","control group, which received standard care - females",continuous,,110,,95,61.07,30.21,63.27,24.79,Group sizes was inferred using Table of characterisitics. Back calculated SD using CI.,FALSE,FALSE,FALSE,TRUE,12997,7944,5795,TEST
135,2450,4574984,Health-Related Quality of Life at 12 month - males,"intervention group, i.e. patient empowerment through information booklet and diary keeping - males","control group, which received standard care - males",continuous,,216,,231,72.49,23.66,71.71,27.1,Group sizes was inferred using Table of characterisitics. Back calculated SD using CI.,FALSE,FALSE,FALSE,TRUE,12997,7944,5795,TEST
136,2448,4574984,postoperative in-hospital stay,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",continuous,,326,,326,,,,,Only median and interquartile range is given.,FALSE,FALSE,FALSE,FALSE,12997,7944,5795,TEST
137,1267,4709985,would have liked more information on acupuncture,tertiary education,other educations,binary,,121,,89,,,,,Specific numbers were not given.,FALSE,FALSE,FALSE,FALSE,3939,3288,2363,TEST
138,3101,4830045,Birth status,Patients in the 3h group,Patients in the 20h group,binary,32,74,22,60,,,,,Used numbers for live birth rate.,FALSE,TRUE,FALSE,TRUE,2530,2096,1505,TEST
139,3100,4830045,Embryo quality,Patients in the 3h group,Patients in the 20h group,binary,,74,,60,,,,,Unclear outcome measures.,FALSE,FALSE,FALSE,FALSE,2530,2096,1505,TEST
140,1275,4880652,SpO2 at 5 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Mean in figure 5's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
141,1272,4880652,the modified Aldrete scores at 60 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Mean and SD are in table that is in graphic form.,FALSE,TRUE,TRUE,FALSE,1406,1149,966,TEST
142,1272,4880652,systolic pressures at 0 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Mean in figure 3's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
143,1272,4880652,"oxygen saturation at 10, 15, 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Means in figure 5's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
144,1272,4880652,"diastolic blood pressure at 10, 15, 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Means in figure 4's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
145,1272,4880652,heart rates,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Means in figure 2's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
146,1272,4880652,visual analogue scores,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Mean and SD are in table that is in graphic form.,FALSE,TRUE,TRUE,FALSE,1406,1149,966,TEST
147,1273,4880652,"systolic blood pressures at 5, 10, 15, and 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Means in figure 3's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
148,1274,4880652,Diastolic blood pressures at 5 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76,,70,,,,,Mean in figure 4's graphics.,TRUE,FALSE,TRUE,FALSE,1406,1149,966,TEST
149,11146,4996097,"""a"" vowel improvement",Septoplasty,Control,continuous,,33,,30,138,,154,,Used F0 (Hz) values. SD is not given.,FALSE,TRUE,FALSE,FALSE,9291,4535,2976,TEST
150,11145,4996097,Total nasal resistance,Septoplasty,Control,continuous,,33,,30,0.25,,0.27,,Used preoperative values. SD is not given.,FALSE,TRUE,FALSE,FALSE,9291,4535,2976,TEST
151,11147,4996097,"""n"" consonant improvement",Septoplasty,Control,continuous,,33,,30,11897,,13229,,Used F0 (Hz) values. SD is not given.,FALSE,TRUE,FALSE,FALSE,9291,4535,2976,TEST
152,13479,5055753,The percentages of patients in the calm,0.2 mg oral clonidine,2 mg oral midazolam,binary,14,40,7,40,,,,,"Even though the outcome says percentage, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,FALSE,FALSE,TRUE,3292,2470,2114,TEST
153,13479,5055753,The percentages of patients in the sedated scale,0.2 mg oral clonidine,2 mg oral midazolam,binary,17,40,7,40,,,,,"Even though the outcome says percentage, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,FALSE,FALSE,TRUE,3292,2470,2114,TEST
154,13480,5055753,the percentages of patients in the agitated sedation scale,0.2 mg oral clonidine,2 mg oral midazolam,binary,,40,,40,,,,,,TRUE,FALSE,FALSE,FALSE,3292,2470,2114,TEST
155,13480,5055753,the percentages of patients in the heavily sedated,0.2 mg oral clonidine,2 mg oral midazolam,binary,,40,,40,,,,,,TRUE,FALSE,FALSE,FALSE,3292,2470,2114,TEST
156,13481,5055753,The mean ¬± SD of intraoperatively administered fentany,0.2 mg oral clonidine,2 mg oral midazolam,continuous,,40,,40,105,30.8,165,34.5,,FALSE,FALSE,FALSE,TRUE,3292,2470,2114,TEST
157,13482,5055753,Mean ± SD of heart rate,0.2 mg oral clonidine,2 mg oral midazolam,continuous,,40,,40,,,,,Info in figure graphics.,TRUE,FALSE,FALSE,FALSE,3292,2470,2114,TEST
158,7710,5056957,Weight reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592,,459,55.91,15.64,56.48,14.76,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,11185,6045,4394,TEST
159,7710,5056957,BMI reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592,,459,21.07,6.39,21.27,5.9,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,11185,6045,4394,TEST
160,7711,5056957,BMI z-score at 12months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592,,459,0.61,1.8,0.66,1.69,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,11185,6045,4394,TEST
161,7712,5056957,Weight reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560,,425,61.08,15.15,61.94,14.25,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,11185,6045,4394,TEST
162,7712,5056957,BMI reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560,,425,21.86,6.22,22.06,5.68,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,11185,6045,4394,TEST
163,7713,5056957,BMI z-score at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560,,425,0.69,1.81,0.71,1.63,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,11185,6045,4394,TEST
164,617,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21,,21,,,,,Data found in table in graphic format.,FALSE,TRUE,TRUE,FALSE,1345,1148,971,TEST
165,615,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21,,21,34.57,14.64,32.76,14.34,,FALSE,FALSE,TRUE,TRUE,1345,1148,971,TEST
166,616,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,binary,8,21,16,21,,,,,,FALSE,FALSE,TRUE,TRUE,1345,1148,971,TEST
167,2797,5079604,Disposition index (DI),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),continuous,,28,,20,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,12690,6902,4923,TEST
168,2797,5079604,incremental area under the curve for insulin (AUCi),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),continuous,,28,,20,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,12690,6902,4923,TEST
169,2792,5079604,hyperglycemia relapse-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,continuous,,17,,16,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,12690,6902,4923,TEST
170,2795,5079604,Cox proportional hazards of failure-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,continuous,,17,,16,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,12690,6902,4923,TEST
171,2793,5079604,The restricted mean time to hyperglycemia relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,continuous,,33,,15,480,,305,,SD is not given.,FALSE,FALSE,FALSE,FALSE,12690,6902,4923,TEST
172,2790,5079604,Hyperglycemia relapse-free survival,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,continuous,,33,,15,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,12690,6902,4923,TEST
173,2791,5079604,The 2-year failure rate,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,binary,13,33,12,15,,,,,Used percentage to calculate events as binary outcome.,TRUE,TRUE,FALSE,TRUE,12690,6902,4923,TEST
174,2796,5079604,The probability of relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,binary,9,33,11,15,,,,,Used percentage to calculate events as binary outcome.,FALSE,FALSE,FALSE,TRUE,12690,6902,4923,TEST
175,10752,5086025,Intuitive eating total score,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26,,26,3.45,0.55,2.54,0.58,Actually comparing preintervention and postintervention,FALSE,TRUE,FALSE,TRUE,29049,17627,13068,TEST
176,10753,5086025,Psychological flexibility,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26,,26,18.23,8.14,22.46,8.67,Actually psychological inflexibility in the article,FALSE,TRUE,FALSE,TRUE,29049,17627,13068,TEST
177,10754,5086025,General mental health,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26,,26,50.24,7.41,45.63,6.31,,FALSE,TRUE,FALSE,TRUE,29049,17627,13068,TEST
178,10755,5086025,Binge eating,Intuitive Eating and Acceptance and Commitment Therapy,Control,binary,7,26,14,26,,,,,,FALSE,FALSE,FALSE,TRUE,29049,17627,13068,TEST
179,10756,5086025,BMI,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26,,26,32.81,5.31,32.93,4.85,,FALSE,TRUE,FALSE,TRUE,29049,17627,13068,TEST
180,10757,5086025,General physical health,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26,,26,50.87,11.02,50.46,7.83,,FALSE,TRUE,FALSE,TRUE,29049,17627,13068,TEST
181,4339,5122613,Left SCTT,Digestion-resistant maltodextrin,Placebo,continuous,,29,,28,10.2,8.6,12.1,9.5,Had to do some simple math to get accurate group size.,FALSE,TRUE,FALSE,TRUE,6184,3742,2832,TEST
182,4340,5122613,Adverse events,Digestion-resistant maltodextrin,Placebo,binary,0,33,0,33,,,,,Based on abstract.,FALSE,FALSE,FALSE,TRUE,6184,3742,2832,TEST
183,4341,5122613,Baseline characteristics and diet,Digestion-resistant maltodextrin,Placebo,continuous,,33,,33,10,4.6,11.5,4.6,Mean daily fiber intake,FALSE,FALSE,FALSE,TRUE,6184,3742,2832,TEST
184,4337,5122613,Improvement in faeces consistency,Digestion-resistant maltodextrin,Placebo,continuous,,33,,33,3.4,1,3.2,0.5,,FALSE,TRUE,FALSE,TRUE,6184,3742,2832,TEST
185,4338,5122613,Colonic transit time,Digestion-resistant maltodextrin,Placebo,continuous,,29,,28,39.7,22.3,48,25,,FALSE,TRUE,FALSE,TRUE,6184,3742,2832,TEST
186,13818,5244530,depression severity reduction,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125,,133,,,,,,TRUE,FALSE,FALSE,FALSE,6216,5516,4050,DEV
187,13818,5244530,remission rate,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125,,133,,,,,,FALSE,FALSE,FALSE,FALSE,6216,5516,4050,DEV
188,13818,5244530,change in quality of life,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125,,133,,,,,,TRUE,FALSE,FALSE,FALSE,6216,5516,4050,DEV
189,13818,5244530,psychological well-being,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125,,133,,,,,,TRUE,FALSE,FALSE,FALSE,6216,5516,4050,DEV
190,13818,5244530,sedative prescriptions,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,52,125,51,133,,,,,Data from 12 months follow up (final timepoint),FALSE,TRUE,FALSE,TRUE,6216,5516,4050,DEV
191,13818,5244530,sick leave,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,49,125,64,133,,,,,,FALSE,TRUE,FALSE,TRUE,6216,5516,4050,DEV
192,13819,5244530,continued antidepressants until the 6-month,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,86,125,78,133,,,,,,FALSE,TRUE,FALSE,TRUE,6216,5516,4050,DEV
193,2094,5360580,Plasma PlsPE,1 mg/day of Pls purified from scallop,placebo,continuous,,138,,131,-0.59,1.11,-0.63,1.08,Data is from after 28 weeks (final timepoint). Back calculated the SD values using CI values.,FALSE,TRUE,FALSE,TRUE,11096,9099,6033,TEST
194,2095,5360580,occurrence of adverse events,1 mg/day of Pls purified from scallop,placebo,binary,39,169,35,167,,,,,,FALSE,TRUE,FALSE,TRUE,11096,9099,6033,TEST
195,2096,5360580,"WMS-R (30 min) In the patients aged 77 years or younger,",1 mg/day of Pls purified from scallop,placebo,continuous,,19,,21,1.84,3.87,0,0.96,Data is from 24 weeks (final timepoint). Back calculated the SD values using CI values.,FALSE,TRUE,FALSE,TRUE,11096,9099,6033,TEST
196,2097,5360580,WMS-R (0 min),1 mg/day of Pls purified from scallop,placebo,continuous,,24,,24,1.29,3.14,1.08,1.55,Data is from 28 weeks (final timepoint). Back calculated the SD values using CI values.,FALSE,TRUE,FALSE,TRUE,11096,9099,6033,TEST
197,7734,5380284,Pain scores 48 hours after the surgery,Gum-chewing group,No gum group,continuous,,38,,37,,,,,,FALSE,TRUE,TRUE,FALSE,1731,1429,1251,TEST
198,7735,5380284,Surgery duration,Gum-chewing group,No gum group,continuous,,38,,37,,,,,Data is unavailable.,FALSE,FALSE,TRUE,FALSE,1731,1429,1251,TEST
199,7736,5380284,Rates of POI,Gum-chewing group,No gum group,binary,,38,,37,,,,,,FALSE,TRUE,TRUE,FALSE,1731,1429,1251,TEST
200,7737,5380284,Consumption of fentanyl,Gum-chewing group,No gum group,continuous,,38,,37,,,,,,FALSE,TRUE,TRUE,FALSE,1731,1429,1251,TEST
201,7738,5380284,Pain scores 24 hours and 72 hours after the surgery,Gum-chewing group,No gum group,continuous,,38,,37,,,,,,FALSE,TRUE,TRUE,FALSE,1731,1429,1251,TEST
202,5498,5380326,Interferon gamma-induced protein 10,Vitamin D supplementation,Control,continuous,,40,,40,636.47,448.47,748.88,551,,FALSE,TRUE,FALSE,TRUE,10658,5810,4260,TEST
203,5496,5380326,Vitamin D levels,Vitamin D supplementation,Control,continuous,,40,,40,45.93,15.37,21.87,5.31,,FALSE,TRUE,FALSE,TRUE,10658,5810,4260,TEST
204,5497,5380326,Th1/Th2 cytokines,Vitamin D supplementation,Control,continuous,,40,,40,,,,,Unclear outcome numerical values in the RCT. Cannot clearly identify the actual metric or measure for the given outcome.,FALSE,FALSE,FALSE,FALSE,10658,5810,4260,TEST
205,5500,5380326,Interleukin 2,Vitamin D supplementation,Control,continuous,,40,,40,4.49,13.34,28.69,103.03,,FALSE,TRUE,FALSE,TRUE,10658,5810,4260,TEST
206,5499,5380326,Dipeptidyl peptidase-4,Vitamin D supplementation,Control,continuous,,40,,40,"6,032.37",1359.15,6408.33,1822.17,Table and text has conflicting numbers. Values are from Table.,FALSE,FALSE,FALSE,TRUE,10658,5810,4260,TEST
207,5501,5380326,Tumor necrosis factor alpha,Vitamin D supplementation,Control,continuous,,40,,40,752.94,1890.16,548.33,1210.9,,FALSE,TRUE,FALSE,TRUE,10658,5810,4260,TEST
208,2913,5459456,inflexion-extension for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,6.3,1.1,6.5,0.9,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
209,2913,5459456,inflexion-extension for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,4,0.3,4,0.6,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
210,2913,5459456,inflexion-extension for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,1.4,0.3,1.3,0.2,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
211,2913,5459456,inflexion-extension for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,1.4,0.1,1.4,0.2,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
212,2913,5459456,lateral bending for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,9.2,0.9,9.6,1.1,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
213,2913,5459456,lateral bending for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,5.8,0.5,5.9,0.7,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
214,2913,5459456,lateral bending for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,2,0.4,1.8,0.2,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
215,2913,5459456,lateral bending for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8,,8,2.2,0.4,2,0.3,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
216,2915,5459456,new bone formation around the screws and bone-implant contact (BIC) in both sections,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating,ACVC,continuous,,8,,8,,,,,,TRUE,FALSE,FALSE,FALSE,13404,7477,5693,TEST
217,2912,5459456,surgery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,67,16,65,13,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
218,2912,5459456,blood loss,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,56,19,51,20,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
219,2912,5459456,recovery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,4.1,2,3.5,1.4,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
220,2912,5459456,time before eating,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,4.5,2.2,3.9,2.3,,FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
221,2914,5459456,Flexion-Extension stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,0.34,0.12,7.47,1.45,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
222,2914,5459456,Lateral bending stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,0.05,0.02,2.67,0.68,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
223,2914,5459456,Rotation stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8,,8,0.02,0,1.62,0.47,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",FALSE,TRUE,FALSE,TRUE,13404,7477,5693,TEST
224,3486,5498715,Scores of external regulation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,0.3,0.79,0.38,0.98,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
225,3486,5498715,Scores of amotivation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,0.33,1.06,0.7,1.24,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
226,3487,5498715,Body mass index,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,25.78,3.3,26.53,3.53,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
227,3484,5498715,Sedentary behavior,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,5.28,2.34,5.75,2.34,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
228,3484,5498715,agility test,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,13.21,1.44,13.8,1.14,Data from followup.,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
229,3483,5498715,Physical activity,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,487.33,111.47,453.57,60.87,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
230,3483,5498715,physical fitness - flexibility,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,35.53,5.87,26.83,5.47,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
231,3483,5498715,physical fitness - muscular endurance,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,17.83,2.7,12.48,2.9,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
232,3483,5498715,physical fitness - agility,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,13.21,1.44,13.8,1.14,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
233,3483,5498715,physical fitness - cardiorespiratory endurance,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,39.1,2.76,37.99,2.14,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
234,3485,5498715,Scores of intrinsic motivation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,10.8,2,4.9,1.88,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
235,3485,5498715,Scores of perception of competence,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,13.6,3.05,14.71,3.87,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
236,3485,5498715,Scores of perception of autonomy,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,26.6,4.43,19.89,4.56,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
237,3485,5498715,Scores of enjoyment,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,27.3,6.77,26,4.68,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
238,3485,5498715,Scores of health care climate,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35,,35,80.5,9.97,69.89,1.59,,FALSE,TRUE,FALSE,TRUE,11299,5431,3973,DEV
239,8054,5534041,composite z-scores in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12,,12,0.11,0.81,-0.25,0.71,,FALSE,TRUE,FALSE,TRUE,6951,5679,4357,TEST
240,8055,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12,,12,6,0.9,4.8,0.9,,FALSE,TRUE,FALSE,TRUE,6951,5679,4357,TEST
241,8053,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),continuous,,12,,12,6,0.9,6.2,1.8,,FALSE,TRUE,FALSE,TRUE,6951,5679,4357,TEST
242,8056,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12,,12,6.2,1.8,4.8,0.9,,FALSE,TRUE,FALSE,TRUE,6951,5679,4357,TEST
243,8057,5534041,composite z-scores in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12,,12,0.13,0.82,-0.25,0.71,,FALSE,TRUE,FALSE,TRUE,6951,5679,4357,TEST
244,10306,5571493,Glycemic level,Dw 5% with Quinine infusion,Dw 5% without Quinine infusion,continuous,,10,,10,0.82,0.05,0.92,0.07,,FALSE,FALSE,FALSE,TRUE,1507,1019,928,TEST
245,10307,5571493,Glycemic level,Saline + Quinine infusion,Dw 5% + Quinine infusion,continuous,,10,,10,0.74,0.05,0.82,0.05,,FALSE,FALSE,FALSE,TRUE,1507,1019,928,TEST
246,10305,5571493,Glycemic level,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10,,10,0.74,0.05,0.83,0.05,,FALSE,FALSE,FALSE,TRUE,1507,1019,928,TEST
247,10308,5571493,QT interval,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10,,10,,,,,No numerical values are given.,FALSE,FALSE,FALSE,FALSE,1507,1019,928,TEST
248,10309,5571493,QT interval,Dw 5%+ Quinine infusion,Dw 5% without Quinine infusion,continuous,,10,,10,,,,,No numerical values are given.,FALSE,FALSE,FALSE,FALSE,1507,1019,928,TEST
249,10310,5571493,Hypoglycemia,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10,,10,,,,,No numerical values are given.,FALSE,FALSE,FALSE,FALSE,1507,1019,928,TEST
250,12425,5614421,The incidence of respiratory distress syndrome,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,42,402,41,388,,,,,,FALSE,TRUE,FALSE,TRUE,25930,11480,8549,TEST
251,12426,5614421,severity of any neonatal respiratory disease,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,8,402,7,388,,,,,,FALSE,TRUE,FALSE,TRUE,25930,11480,8549,TEST
252,12427,5614421,other respiratory morbidities,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,,402,,388,,,,,Unclear what measurement to use.,FALSE,FALSE,FALSE,FALSE,25930,11480,8549,TEST
253,12427,5614421,"adverse infant outcomes, including serious infant composite outcome",vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,155,406,152,393,,,,,,FALSE,TRUE,FALSE,TRUE,25930,11480,8549,TEST
254,12428,5614421,side effects,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,134,394,118,382,,,,,,FALSE,TRUE,FALSE,TRUE,25930,11480,8549,TEST
255,10572,5711682,In-stent late lumen loss at 9 months,Genoss drug-eluting stent (DES),Promus Element,continuous,,38,,39,0.11,0.25,0.16,0.43,,FALSE,TRUE,FALSE,TRUE,13148,4660,2966,TEST
256,10573,5711682,myocardial infarction (MI),Genoss drug-eluting stent (DES),Promus Element,binary,0,38,0,39,,,,,,FALSE,TRUE,FALSE,TRUE,13148,4660,2966,TEST
257,10571,5711682,target lesion revascularization (TLR),Genoss drug-eluting stent (DES),Promus Element,binary,1,38,1,39,,,,,,FALSE,TRUE,FALSE,TRUE,13148,4660,2966,TEST
258,10574,5711682,stent thrombosis,Genoss drug-eluting stent (DES),Promus Element,binary,0,38,0,39,,,,,,FALSE,TRUE,FALSE,TRUE,13148,4660,2966,TEST
259,10575,5711682,rates of death,Genoss drug-eluting stent (DES),Promus Element,binary,1,38,0,39,,,,,,FALSE,TRUE,FALSE,TRUE,13148,4660,2966,TEST
260,13181,5771543,CGI-I response rate,fluoxetine,placebo,binary,79,101,62,99,,,,,,FALSE,TRUE,FALSE,TRUE,12534,9831,7366,DEV
261,13182,5771543,CGI-I response rate,desvenlafaxine,placebo,binary,68,99,62,99,,,,,,FALSE,TRUE,FALSE,TRUE,12534,9831,7366,DEV
262,13183,5771543,Treatment-emergent adverse events (TEAEs),desvenlafaxine,placebo,binary,69,115,79,112,,,,,,FALSE,TRUE,FALSE,TRUE,12534,9831,7366,DEV
263,13183,5771543,Treatment-emergent adverse events (TEAEs),fluoxetine,placebo,binary,72,112,79,112,,,,,Typo in the table,FALSE,TRUE,FALSE,TRUE,12534,9831,7366,DEV
264,2786,2430617,HBeAg sero-conversion rate,60 µg of immune complexes (YIC),placebo,binary,17,78,7,78,,,,,effects found in abstract and exact number in results table,FALSE,TRUE,FALSE,TRUE,7987,4896,3773,TEST
265,2787,2430617,adverse events,30 µg YIC,placebo,binary,3,83,4,79,,,,,,FALSE,TRUE,FALSE,TRUE,7987,4896,3773,TEST
266,2787,2430617,adverse events,60 µg of YIC,placebo,binary,4,80,4,79,,,,,effects found in abstract and number of samples in text,FALSE,FALSE,FALSE,TRUE,7987,4896,3773,TEST
267,12440,2596788,GERD-knowledge,education,control,continuous,,102,,109,17.1,,14,,no standard deviations given,TRUE,FALSE,FALSE,FALSE,5143,3554,2520,TEST
268,2991,3214395,laryngoscopy duration,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 45",group 3 involved bispectral index (BIS) of 35,continuous,,60,,30,,,,,mean and std not given for group 1 and 2 combined,FALSE,TRUE,TRUE,FALSE,1201,996,880,TEST
269,2991,3214395,laryngospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 46",group 3 involved bispectral index (BIS) of 36,binary,,60,,30,,,,,,FALSE,TRUE,TRUE,FALSE,1201,996,880,TEST
270,2991,3214395,bronchospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 47",group 3 involved bispectral index (BIS) of 37,binary,,60,,30,,,,,,FALSE,TRUE,TRUE,FALSE,1201,996,880,TEST
271,2991,3214395,laryngoscopy failure,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 48",group 3 involved bispectral index (BIS) of 38,continuous,,60,,30,,,,,mean and std not given for group 1 and 2 combined,FALSE,TRUE,TRUE,FALSE,1201,996,880,TEST
272,2991,3214395,extremity movement,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 49",group 3 involved bispectral index (BIS) of 39,binary,,60,,30,,,,,,FALSE,TRUE,TRUE,FALSE,1201,996,880,TEST
273,2991,3214395,awakening,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 50",group 3 involved bispectral index (BIS) of 40,continuous,,60,,30,,,,,mean and std not given for group 1 and 2 combined,FALSE,TRUE,TRUE,FALSE,1201,996,880,TEST
274,6419,3654355,Body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,-17.5,6.1,-0.5,2.8,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
275,6420,3654355,Fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,-15.7,5.3,-0.4,5,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
276,6421,3654355,Visceral fat,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,-82.3,31.6,4.3,22.7,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
277,6422,3654355,Baseline Height,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,173.2,8.6,172.3,10.4,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
278,6422,3654355,Baseline body mass index,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,42.8,4.6,42.8,6.3,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
279,6422,3654355,baseline body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,128.9,19.4,127.1,21.6,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
280,6422,3654355,baseline fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,60.5,11,60.4,13.5,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
281,6422,3654355,baseline fat-free mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,68.3,13.2,67.1,12.8,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
282,6422,3654355,baseline skeletal muscle mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,38.4,7.9,37.9,7.4,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
283,6422,3654355,baseline visceral fat area,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71,,33,255.7,64.7,245.6,66.3,,FALSE,TRUE,FALSE,TRUE,18948,9604,6664,TEST
284,6301,3929816,Baseline characteristics and general anesthesia procedure,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10,,10,,,,,No quantitative measures given,FALSE,FALSE,FALSE,FALSE,1047,859,749,TEST
285,6302,3929816,Pathologic changes in the liver,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10,,10,,,,,No quantitative measures given,FALSE,FALSE,FALSE,FALSE,1047,859,749,TEST
286,6303,3929816,Pathologic changes in the kidneys,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10,,10,20,,,,Not enough measures given for calculation,FALSE,FALSE,FALSE,FALSE,1047,859,749,TEST
287,6100,4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,,,,,"F-values given, not sure how to use them",FALSE,FALSE,FALSE,FALSE,7350,5561,4156,TEST
288,6102,4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,treatment as usual (TAU),continuous,,19,,19,,,,,"F-values given, not sure how to use them",FALSE,FALSE,FALSE,FALSE,7350,5561,4156,TEST
289,6103,4215531,MCCB performance : Processing Speed,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,44.6,12.2,48.2,12.3,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7350,5561,4156,TEST
290,6103,4215531,MCCB performance : Attentional Vigilance,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,38.5,11.8,41.3,10.1,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7350,5561,4156,TEST
291,6103,4215531,MCCB performance : Visual Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,49.4,12.8,46.5,9.8,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7350,5561,4156,TEST
292,6104,4215531,MCCB performance : Working Memory,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,48.2,9.2,50.8,12.1,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7351,5561,4156,TEST
293,6104,4215531,MCCB performance : Verbal Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,47.1,10,47.3,10.4,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7352,5561,4156,TEST
294,6104,4215531,MCCB performance : Reasoning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,47.9,8.8,46.5,9.8,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7353,5561,4156,TEST
295,6104,4215531,MCCB performance : Social Cognition,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19,,19,39.3,11.1,42.8,11.7,used post values and Treatment as Usual as Baseline,FALSE,FALSE,FALSE,TRUE,7350,5561,4156,TEST
296,5595,4355974,Days of wheeze,BostonBreathes system,Control,continuous,,28,,14,-1.4,,-4.2,,standard deviations not given and means are mean change,FALSE,TRUE,FALSE,FALSE,7450,5464,3820,TEST
297,5596,4355974,ER visits,BostonBreathes system,Control,binary,1,28,1,14,,,,,found in table,FALSE,TRUE,FALSE,TRUE,7450,5464,3820,TEST
298,5597,4355974,Days limited activity from asthma,BostonBreathes system,Control,continuous,,28,,14,-0.2,,-1.8,,"standard deviations not given, means are mean change",FALSE,TRUE,FALSE,FALSE,7450,5464,3820,TEST
299,5598,4355974,Knowledge,BostonBreathes system,Control,binary,9,12,3,8,,,,,"found in table,",FALSE,TRUE,FALSE,TRUE,7450,5464,3820,TEST
300,5599,4355974,School days missed for asthma,BostonBreathes system,Control,continuous,,28,,14,-0.2,,-0.4,,"standard deviations not given, means are mean change",FALSE,TRUE,FALSE,FALSE,7450,5464,3820,TEST
301,5600,4355974,Days patient had to slow down,BostonBreathes system,Control,continuous,,28,,14,-1.4,,-0.4,,"standard deviations not given, means are mean change",FALSE,TRUE,FALSE,FALSE,7450,5464,3820,TEST
302,3878,4357072,improvement in symptom scores,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,continuous,,15,,15,0.2,0.4,0.8,0.6,significance found in abstract and numbers in results,FALSE,TRUE,TRUE,TRUE,2097,1624,1385,TEST
303,3879,4357072,reduction in burning sensation,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,continuous,,15,,15,1,2.1,5.3,6.1,significance found in abstract and numbers in results,FALSE,TRUE,TRUE,TRUE,2097,1624,1385,TEST
304,3880,4357072,reduction in erythematous area,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,binary,14,15,10,15,,,,,significance found in abstract and numbers in results,FALSE,TRUE,TRUE,TRUE,2097,1624,1385,TEST
305,3882,4357072,reappearance of erythematous areas after 2 months posttreatment,pimecrolimus,triamcinolone acetate,binary,1,15,5,15,,,,,significance found in abstract and numbers in results,FALSE,TRUE,FALSE,TRUE,2097,1624,1385,TEST
306,7831,4541185,duration of sensory block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,703.83,42.9,556.38,37.96,found in text,FALSE,TRUE,TRUE,TRUE,1359,1043,907,TEST
307,7831,4541185,duration of motor block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,621.67,46.76,500.86,44.58,found in text,FALSE,TRUE,TRUE,TRUE,1359,1043,907,TEST
308,7832,4541185,duration of analgesia,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,878.33,89.955,613.1,51.797,found in text,FALSE,TRUE,TRUE,TRUE,1359,1043,907,TEST
309,7833,4541185,onset of sensory block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,4.36,0.81,4.84,0.65,found in abstract,FALSE,FALSE,FALSE,TRUE,1359,1043,907,TEST
310,7833,4541185,onset of motor block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,9.83,1.12,10.85,0.79,found in abstract,FALSE,FALSE,FALSE,TRUE,1359,1043,907,TEST
311,7834,4541185,drop in heart rate,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,,,,,found in table,FALSE,TRUE,TRUE,FALSE,1359,1043,907,TEST
312,7835,4541185,drop in mean arterial pressure,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30,,30,,,,,found in table,FALSE,TRUE,TRUE,FALSE,1359,1043,907,TEST
313,9840,4928400,Stone-free rate,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,binary,22,22,16,20,,,,,,FALSE,TRUE,FALSE,TRUE,4037,2288,1670,TEST
314,9841,4928400,Operative time,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22,,20,74.1,12.2,78,6.4,found in table,FALSE,TRUE,FALSE,TRUE,4037,2288,1670,TEST
315,9842,4928400,Complication,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,binary,5,22,7,20,,,,,,FALSE,TRUE,FALSE,TRUE,4037,2288,1670,TEST
316,9843,4928400,Postoperative pain,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22,,20,4.3,1,3.6,1.2,,FALSE,TRUE,FALSE,TRUE,4037,2288,1670,TEST
317,9844,4928400,Hospital stay,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22,,20,4.2,1.2,2.1,1.1,,FALSE,TRUE,FALSE,TRUE,4037,2288,1670,TEST
318,9845,4928400,Time for return to daily activities,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22,,20,13.3,1.7,9,1.6,,FALSE,TRUE,FALSE,TRUE,4037,2288,1670,TEST
319,4723,5539943,reflections of sustain talk,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,5076,3578,TEST
320,4724,5539943,"""sustain talk"" (ST)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,continuous,,,,,,,,,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,5076,3578,TEST
321,4725,5539943,"Frequency of client ""change talk"" (CT)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,5076,3578,TEST
322,4726,5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,continuous,,,,,,,,,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,5076,3578,TEST
323,4726,5539943,Motivational Interviewing (MI) knowledge,MI training (MI-AU),baseline,continuous,,,,,,,,,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,5076,3578,TEST
324,4727,5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,5076,3578,TEST
325,5372,5559992,Anxiety,Buprenophine 32 mg,No treatment,continuous,,5,,5,,,,,"decided ""no treatment"" meant baseline",FALSE,TRUE,TRUE,FALSE,1146,884,721,TEST
326,5373,5559992,Anxiety,Buprenophine 64 mg,No treatment,continuous,,4,,4,,,,,"decided ""no treatment"" meant baseline",FALSE,TRUE,TRUE,FALSE,1146,884,721,TEST
327,5374,5559992,Anxiety,Buprenophine 96 mg,No treatment,continuous,,5,,5,,,,,"decided ""no treatment"" meant baseline",FALSE,TRUE,TRUE,FALSE,1146,884,721,TEST
328,5375,5559992,Anxiety,Buprenophine 32 mg,Buprenophine 64 mg,continuous,,5,,4,,,,,found in table,FALSE,TRUE,TRUE,FALSE,1146,884,721,TEST
329,5376,5559992,Anxiety,Buprenophine 32 mg,Buprenophine 96 mg,continuous,,5,,5,,,,,found in table,FALSE,TRUE,TRUE,FALSE,1146,884,721,TEST
330,5377,5559992,Anxiety,Buprenophine 64 mg,Buprenophine 96 mg,continuous,,4,,5,,,,,found in table,FALSE,TRUE,TRUE,FALSE,1146,884,721,TEST
331,5078,5617873,Parent-rated Aberrant Behavior Checklis improvement,Aripiprazole,Placbeo,continuous,,45,,47,-11.4,1.3,-7.5,1.4,"all means and std found in table 2, given as mean change from baseline",FALSE,TRUE,FALSE,TRUE,7551,5383,4396,TEST
332,5079,5617873,Clinician-rated Clinical Global Impression-Improvement scores,Aripiprazole,Placbeo,continuous,,47,,45,2.4,0.1,3.4,0.1,raw values foun din text,FALSE,FALSE,FALSE,TRUE,7551,5383,4396,TEST
333,5080,5617873,Serious adverse effects,Aripiprazole,Placbeo,binary,0,47,1,45,,,,,all means and std found in table 2,FALSE,TRUE,FALSE,TRUE,7551,5383,4396,TEST
334,5081,5617873,Inappropriate speech,Aripiprazole,Placbeo,continuous,,45,,47,-2.2,0.4,-1.5,0.4,"table 2, given as mean change",FALSE,TRUE,FALSE,TRUE,7551,5383,4396,TEST
335,5082,5617873,Social withdrawal,Aripiprazole,Placbeo,continuous,,45,,47,-4.7,1.1,-5.2,1,"table 2, given as mean change",FALSE,TRUE,FALSE,TRUE,7551,5383,4396,TEST
336,5083,5617873,Compulsion scale,Aripiprazole,Placbeo,continuous,,45,,47,-1.3,0.5,-2,0.5,"table 2, given as mean change",FALSE,TRUE,FALSE,TRUE,7551,5383,4396,TEST
337,11078,5655920,Nausea,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,2094,,637,,,,,placebo-adjusted meta-analysis (fixed effect) = -0.1,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
338,11078,5655920,vomiting,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,2094,,637,,,,,placebo-adjusted meta-analysis (fixed effect) = -0.1,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
339,11079,5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,122,,637,,,,,placebo-adjusted meta-analysis (fixed effect) = 0.04,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
340,11079,5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,122,,637,,,,,placebo-adjusted meta-analysis (fixed effect) = 0.04,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
341,11080,5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,binary,,122,,2094,,,,,placebo-adjusted meta-analysis (fixed effect) = -0.03,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
342,11080,5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,binary,,122,,2094,,,,,placebo-adjusted meta-analysis (fixed effect) = -0.03,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
343,11081,5655920,Hypoglycaemia,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,2094,,637,,,,,placebo-adjusted meta-analysis (fixed effect) = -0.02,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
344,11082,5655920,Hypoglycaemia,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,122,,637,,,,,placebo-adjusted meta-analysis (fixed effect) = 0.04,FALSE,TRUE,FALSE,FALSE,13081,5825,4026,TEST
345,10232,5686687,Pain,Resveratrol,Placebo,continuous,,22,,22,2.3,2.63,3.9,3.35,Back calculated the SD values from CI.,FALSE,TRUE,FALSE,TRUE,7451,3515,2366,TEST
346,10233,5686687,Need for dipyrone,Resveratrol,Placebo,continuous,,22,,22,1944,1793,625,250,found in table,FALSE,TRUE,FALSE,TRUE,7451,3515,2366,TEST
347,10234,5686687,Need for Ibuprofen,Resveratrol,Placebo,continuous,,22,,22,1200,848,5640,328,found in table,FALSE,TRUE,FALSE,TRUE,7451,3515,2366,TEST
348,10235,5686687,Prolactin levels,Resveratrol,Placebo,continuous,,22,,22,,,,,median and ranges given,FALSE,TRUE,FALSE,FALSE,7451,3515,2366,TEST
349,10236,5686687,CA-125 levels,Resveratrol,Placebo,continuous,,22,,22,,,,,median and ranges given,FALSE,TRUE,FALSE,FALSE,7451,3515,2366,TEST
350,4493,5874317,Knee extension (1-rep Max),Bilateral training,Unilateral training,continuous,,9,,9,237.2,51,182.4,8.4,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,5696,4631,TEST
351,4494,5874317,Knee flexion (1-rep Max),Bilateral training,Unilateral training,continuous,,9,,9,99.8,10.2,86.8,2.9,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,5696,4631,TEST
352,4495,5874317,Change of direction improvement,Bilateral training,Unilateral training,continuous,,9,,9,5.46,0.2,5.67,0.16,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,5696,4631,TEST
353,4496,5874317,Squat jump,Bilateral training,Unilateral training,continuous,,9,,9,0.37,0.04,0.34,0.04,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,5696,4631,TEST
354,4497,5874317,Horizontal countermovement jump,Bilateral training,Unilateral training,continuous,,9,,9,2.34,0.07,2.21,0.15,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,5696,4631,TEST
355,4498,5874317,Horizontal triple jump (non-dominant leg),Bilateral training,Unilateral training,continuous,,9,,9,5.71,0.71,5.7,0.45,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,5696,4631,TEST
356,4710,5884950,objective-SCORAD score,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,continuous,,13,,13,,,,,"mean and std not given, only median and interquartile range",FALSE,FALSE,FALSE,FALSE,11712,6635,5281,TEST
357,4711,5884950,chemokines CXCL9,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,continuous,,13,,13,,,,,"mean and std not given, only median and interquartile range",FALSE,FALSE,FALSE,FALSE,11712,6635,5281,TEST
358,8710,5971365,clinically meaningful improvement at week 144 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,188,287,144,277,,,,,"counts calculated from percentages given in text, totals found in figure",FALSE,FALSE,FALSE,TRUE,3177,2394,2130,TEST
359,8711,5971365,Symbol Digit Modalities Test (SDMT) score at week 96,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,continuous,,720,,682,4.1,12.4,2.9,12.7,"found in figure and text, totals found in figure",TRUE,FALSE,FALSE,TRUE,3177,2394,2130,TEST
360,8712,5971365,Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,continuous,,287,,277,6.3,12.6,3.1,13.2,"found in figure and text, totals found in figure",FALSE,FALSE,FALSE,TRUE,3177,2394,2130,TEST
361,8713,5971365,clinically meaningful worsening at week 96 (⩾3-point decrease on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,140,720,169,682,,,,,"counts calculated from percentages given in text, totals found in figure",TRUE,FALSE,FALSE,TRUE,3177,2394,2130,TEST
362,8714,5971365,clinically meaningful improvement at week 96 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,432,720,369,682,,,,,"counts calculated from percentages given in text, totals found in figure",TRUE,FALSE,FALSE,TRUE,3177,2394,2130,TEST
363,12884,5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,continuous,,20,,25,23.1,25.6,98.3,104.6,found in table,FALSE,TRUE,FALSE,TRUE,4402,2905,2274,TEST
364,12885,5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)","GDM2 (less tight glycaemic targets, <5.3_mmol/L and <_7.8_mmol/L)",continuous,,20,,21,23.1,25.6,21.5,25.8,found in table,FALSE,TRUE,FALSE,TRUE,4402,2905,2274,TEST
365,12886,5976949,leptin/adiponectin ratio (LAR),"GDM2 (less tight glycaemic targets, <5.3 mmol/L and < 7.8 mmol/L)","GDM1 (tight glycaemic targets, fasting blood glucose_<_5.1_mmol/L and <7.0_mmol/L postprandial) postprandial,), control group- normal glucose tolerance",continuous,,21,,45,1.7,1.66,,,combined means and stds not given,FALSE,TRUE,FALSE,FALSE,4402,2905,2274,TEST
366,12887,5976949,leptin/adiponectin ratio (LAR),"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,continuous,,20,,25,0.97,1.31,0.72,0.46,found in table,FALSE,TRUE,FALSE,TRUE,4402,2905,2274,TEST
367,224,1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59,,64,45,,57,,Only the mean score was given in table.,FALSE,TRUE,FALSE,FALSE,4361,3649,2573,TEST
368,216,1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59,,64,1,,5,,Only the mean change was found in text.,FALSE,FALSE,FALSE,FALSE,4361,3649,2573,TEST
369,217,1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,binary,51,59,57,64,,,,,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,4361,3649,2573,TEST
370,218,1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,binary,35,59,33,64,,,,,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,4361,3649,2573,TEST
371,228,1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59,,64,45,,57,,Only the mean score was given in table.,FALSE,TRUE,FALSE,FALSE,4361,3649,2573,TEST
372,226,1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59,,64,,,,,Only the overall mean difference in score improvement was given.,FALSE,FALSE,FALSE,FALSE,4361,3649,2573,TEST
373,220,1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,32,59,46,64,,,,,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,4361,3649,2573,TEST
374,227,1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59,,64,,,,,Only the overall mean difference in score improvement was given.,FALSE,FALSE,FALSE,FALSE,4361,3649,2573,TEST
375,219,1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,binary,23,59,28,64,,,,,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,4361,3649,2573,TEST
376,223,1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,,59,,64,,,,,Unclear since the values for this are reported with ACEI intake.,FALSE,TRUE,FALSE,FALSE,4361,3649,2573,TEST
377,222,1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,25,59,19,64,,,,,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,4361,3649,2573,TEST
378,221,1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,,59,,64,,,,,Unclear since the values for this are reported with ARB intake.,FALSE,TRUE,FALSE,FALSE,4361,3649,2573,TEST
379,214,1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,binary,25,59,39,64,,,,,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,4361,3649,2573,TEST
380,215,1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,binary,47,59,19,64,,,,,Used percentage found in text to calculate actual number for binary variable.,FALSE,FALSE,FALSE,TRUE,4361,3649,2573,TEST
381,225,1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,binary,20,59,25,64,,,,,Used percentage found in text to calculate actual number for binary variable.,FALSE,FALSE,FALSE,TRUE,4361,3649,2573,TEST
382,876,2974815,discontinued treatment,"""phone calls"" group","""no phone calls"" group",binary,4,108,30,246,,,,,Values from results section text.,FALSE,FALSE,FALSE,TRUE,13659,6016,4469,TEST
383,949,3278655,maximum total point motion (MTPM),The trabecular metal tibial monoblock component (TM),cemented component.,continuous,,27,,18,0.98,3.91,0.79,2.27,Back calculated the SD values from CI. Numerical values are from 5-year follow up.,FALSE,TRUE,FALSE,TRUE,5463,3510,2857,TEST
384,877,2974815,The percentage of patients with controlled blood pressure (<140/90 mmHg),"""phone calls"" group","""no phone calls"" group",binary,,108,,246,,,,,Numerical values are not available.,FALSE,FALSE,FALSE,FALSE,13659,6016,4469,TEST
385,1118,3577738,website use in terms of the number of pages visited,website with social presence elements.,website without social presence elements.,continuous,,,,,7.5,4,8,3.8,Cannot find the group sizes in the text or table.,FALSE,TRUE,FALSE,FALSE,3018,2080,1653,TEST
386,1118,3577738,website use in terms of time on the website,website with social presence elements.,website without social presence elements.,continuous,,,,,151,117.4,150.8,107.8,Cannot find the group sizes in the text or table.,FALSE,TRUE,FALSE,FALSE,3018,2080,1653,TEST
387,1119,3577738,focused on the social presence elements in terms of frequency,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
388,1119,3577738,focused on the social presence elements in terms of duration,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
389,875,2974815,percentage of patients with controlled blood pressure,"""phone calls"" group","""no phone calls"" group",binary,86,108,175,246,,,,,"Used 80% for ""phone calls"" group and 71% for ""no phone calls"" group.",FALSE,FALSE,FALSE,TRUE,13659,6016,4469,TEST
390,950,3278655,subsidence,The trabecular metal tibial monoblock component (TM),cemented component.,continuous,,27,,18,-0.38,0.37,-0.04,0.11,Used numerical values for Superior/inferior translation (SD). Numerical values are from 5-year follow up.,FALSE,TRUE,FALSE,TRUE,5463,3510,2857,TEST
391,951,3278655,"The proportion of ""at risk"" components at 5 years",The trabecular metal tibial monoblock component (TM),cemented component.,binary,0,27,2,18,,,,,Used numerical values from 5-year follow up provided in abstract.,FALSE,FALSE,FALSE,TRUE,5463,3510,2857,TEST
392,1120,3577738,efficiency,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
393,1120,3577738,effectiveness,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
394,1120,3577738,enjoyment,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
395,1120,3577738,active trust,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
396,1120,3577738,interest,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,3018,2080,1653,TEST
397,2240,4678179,progression-free-survival (PFS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53,,53,,,,,Median was only given.,FALSE,FALSE,FALSE,FALSE,9517,6474,5204,TEST
398,2241,4678179,Median overall survival (OS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53,,53,6.9,4.09,6.1,5.57,"Median is given with CI. Since the outcome explicitly says ""median"", including median values. Back calculated SD using CI.",FALSE,FALSE,FALSE,TRUE,9517,6474,5204,TEST
399,2242,4678179,Response rates,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53,,53,8,,13,,Only difference in response rates as percent is given.,FALSE,FALSE,FALSE,FALSE,9517,6474,5204,TEST
400,2243,4678179,rate of adverse events,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),binary,4,53,2,53,,,,,Used numbers found in results section text.,FALSE,FALSE,FALSE,TRUE,9517,6474,5204,TEST
401,2723,5268424,score on the general dimension scale of negative affects (referred to as NA from here onward),view a video featuring individuals that live in extreme poverty,control,continuous,,55,,50,21.036,6.327,17.68,5.859,,FALSE,TRUE,FALSE,TRUE,12258,6615,4148,TEST
402,2804,5781260,Exercise-induced Creatine kinase (CK),lemon verbena extract,placebo,continuous,,20,,20,,,,,Mean and CI in figure.,TRUE,FALSE,FALSE,FALSE,4385,3505,2662,TEST
403,2802,5781260,exercise-related loss of muscle strength,lemon verbena extract,placebo,continuous,,20,,20,,,,,Mean and CI in figure.,TRUE,FALSE,FALSE,FALSE,4385,3505,2662,TEST
404,2805,5781260,Glutathione peroxidase (GPxP),lemon verbena extract,placebo,continuous,,20,,20,,,,,Mean and CI in figure.,TRUE,FALSE,FALSE,FALSE,4385,3505,2662,TEST
405,2807,5781260,adverse events,lemon verbena extract,placebo,binary,,20,,20,,,,,Unclear numerical values.,FALSE,FALSE,FALSE,FALSE,4385,3505,2662,TEST
406,2803,5781260,Movement induced pain (VAS),lemon verbena extract,placebo,continuous,,20,,20,,,,,Mean and CI in figure.,FALSE,FALSE,FALSE,FALSE,4385,3505,2662,TEST
407,2806,5781260,Interleukin 6,lemon verbena extract,placebo,continuous,,20,,20,,,,,Numerical values are not given.,FALSE,FALSE,FALSE,FALSE,4385,3505,2662,TEST
408,3260,3475525,Correct selection of the healthier product,MTL+caloric intake group,No label group,continuous,,90,,99,73.3,6.9,67.8,10.3,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
409,3260,3475525,Correct selection of the healthier product,MTL+caloric intake group,TL+SNL group,continuous,,90,,95,73.3,6.9,65.8,7.3,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
410,3260,3475525,Correct selection of the healthier product,choices group,No label group,continuous,,98,,99,72.5,13.2,67.8,10.3,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
411,3260,3475525,Correct selection of the healthier product,choices group,TL+SNL group,continuous,,98,,95,72.5,13.2,65.8,7.3,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
412,3262,3475525,Taste perception,MTL group,No label group,continuous,,98,,99,5.6,1.4,5.8,1.4,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
413,3262,3475525,Taste perception,MTL+caloric intake group,No label group,continuous,,90,,99,5.4,1.4,5.8,1.4,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
414,3262,3475525,Taste perception,MTL group,choices group,continuous,,98,,98,5.6,1.4,5.3,1.5,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
415,3262,3475525,Taste perception,MTL+caloric intake group,choices group,continuous,,90,,98,5.4,1.4,5.3,1.5,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
416,3262,3475525,intent of purchase,MTL group,No label group,continuous,,98,,99,3.8,1.4,4.1,1.5,Used values for self.,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
417,3262,3475525,intent of purchase,MTL+caloric intake group,No label group,continuous,,90,,99,3.6,1.4,4.1,1.5,Used values for self.,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
418,3262,3475525,intent of purchase,MTL group,choices group,continuous,,98,,98,3.8,1.4,4.1,1.7,Used values for self.,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
419,3262,3475525,intent of purchase,MTL+caloric intake group,choices group,continuous,,90,,98,3.6,1.5,4.1,1.7,Used values for self.,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
420,3401,3877023,quantitative contour sharpness of the Cervicothoracic Spine,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18,,21,0.95,0.24,1.43,0.48,"Original outcome was ""quantitative contour sharpness"".",FALSE,FALSE,FALSE,TRUE,17694,9686,7100,TEST
421,3401,3877023,quantitative contour sharpness of the thoracolumbar spine,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30,,34,0.83,0.22,1.32,0.51,"Original outcome was ""quantitative contour sharpness"".",FALSE,FALSE,FALSE,TRUE,17694,9686,7100,TEST
422,3402,3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18,,21,18.1,11.6,9.3,5.5,,FALSE,TRUE,FALSE,TRUE,17694,9686,7100,TEST
423,3402,3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30,,34,22.3,13.2,14,5.6,,FALSE,TRUE,FALSE,TRUE,17694,9686,7100,TEST
424,3402,3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18,,21,19.3,10.3,8.2,5.7,,FALSE,TRUE,FALSE,TRUE,17694,9686,7100,TEST
425,3402,3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30,,34,24,12.9,11.7,6.3,,FALSE,TRUE,FALSE,TRUE,17694,9686,7100,TEST
426,3403,3877023,Scanning times,high-field horizontal open MR scanner,short-bore MR scanner,continuous,,49,,44,32,22,20,9,,FALSE,FALSE,FALSE,TRUE,17694,9686,7100,TEST
427,3404,3877023,The mean signal-to-noise (SNR) values,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,44,,49,17.97,6.58,11.28,4.35,,FALSE,FALSE,FALSE,TRUE,17694,9686,7100,TEST
428,3261,3475525,Scores on the saturated fat quiz,MTL group,No label group,continuous,,98,,99,90.7,20.4,33.6,16.3,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
429,3261,3475525,Scores on the saturated fat quiz,MTL+caloric intake group,No label group,continuous,,90,,99,92.3,15.1,33.6,16.3,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
430,3261,3475525,Scores on the saturated fat quiz,MTL group,choices group,continuous,,98,,98,90.7,20.4,35.7,15.9,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
431,3261,3475525,Scores on the saturated fat quiz,MTL+caloric intake group,choices group,continuous,,90,,98,92.3,15.1,35.7,15.9,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
432,3261,3475525,Scores on sugar quiz,MTL group,No label group,continuous,,98,,99,90,20.7,47.2,19.6,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
433,3261,3475525,Scores on sugar quiz,MTL+caloric intake group,No label group,continuous,,90,,99,92.6,15.5,47.2,19.6,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
434,3261,3475525,Scores on sugar quiz,MTL group,choices group,continuous,,98,,98,90,20.7,41.9,19.4,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
435,3261,3475525,Scores on sugar quiz,MTL+caloric intake group,choices group,continuous,,90,,98,92.6,15.5,41.9,19.4,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
436,3261,3475525,Scores on sodium quiz,MTL group,No label group,continuous,,98,,99,93.5,16.4,42.6,20.7,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
437,3261,3475525,Scores on sodium quiz,MTL+caloric intake group,No label group,continuous,,90,,99,94.1,15.6,42.6,20.7,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
438,3261,3475525,Scores on sodium quiz,MTL group,choices group,continuous,,98,,98,93.5,16.4,47.1,21.1,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
439,3261,3475525,Scores on sodium quiz,MTL+caloric intake group,choices group,continuous,,90,,98,94.1,15.6,47.1,21.1,,FALSE,TRUE,FALSE,TRUE,9086,4934,3542,TEST
440,8803,4467620,decrease in exercise intensity as time elapsed (at time 10),Hot + Cooling conditions,Hot conditions,continuous,,8,,8,114.6,35.6,123.9,30.2,Added the last timepoint to the outcome name. Since there are 10 different time points.,FALSE,TRUE,FALSE,TRUE,7288,4607,3858,TEST
441,8804,4467620,weight reduction,Hot + Cooling conditions,Hot conditions,continuous,,8,,8,68.6,7.7,68.8,7.5,The numerical values are from Exercise state.,FALSE,TRUE,FALSE,TRUE,7288,4607,3858,TEST
442,8805,4467620,accuracy of the cognitive tasks,Exercise - Hot + Cooling conditions,At rest - Hot + Cooling conditions,continuous,,8,,8,,,,,,TRUE,FALSE,FALSE,FALSE,7288,4607,3858,TEST
443,8801,4467620,accuracy of the cognitive tasks,Exercise - Hot condition,At rest - Hot condition,continuous,,8,,8,,,,,,TRUE,FALSE,FALSE,FALSE,7288,4607,3858,TEST
444,8802,4467620,differences in the accuracy,Hot + Cooling conditions,Hot conditions,continuous,,8,,8,,,,,,TRUE,FALSE,FALSE,FALSE,7288,4607,3858,TEST
445,4098,4140238,ocular itching for visit 3B at 7 min,bepotastine besilate ophthalmic solution (BBOS) 1.5%,placebo,continuous,,70,,70,1.2,,2.1,,"Original outcome name is ""ocular itching"". However, due to many different visits and data from timepoints. We specified this in the outcome. Visit 3B was the first study they conducted and 7 min is the last timepoint. No SD information was given",FALSE,TRUE,FALSE,FALSE,12685,6812,5052,TEST
446,4002,4879328,waist circumference,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104,,114,-0.89,3.32,0.3,3.54,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
447,4003,4879328,effects for walking,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104,,114,-0.55,2.29,0.31,3.84,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
448,4003,4879328,effects for vigorous activity,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104,,114,0.2,1.56,-0.4,2.48,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
449,4004,4879328,FFBQ Total Index Score,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104,,114,0.07,0.26,0.01,0.33,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
450,4005,4879328,weekly moderate physical activity sessions,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104,,114,0.19,1.82,-0.68,2.32,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
451,4006,4879328,accelerometer-assessed moderate to vigorous physical activity (MVPA),"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,99,,108,7.41,66.12,-16.1,66.25,Values are from Accelerometer PA in Table 2. Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
452,4001,4879328,weight loss,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104,,114,-0.89,3.33,0.3,3.54,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,12872,8442,5640,TEST
453,4432,5726464,Glucose,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
454,4432,5726464,insulin,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
455,4422,4483334,Amount of calcium and phosphate on enamel surface,CPP-ACP plus laser (group D),Distilled and deionized water (group A),continuous,,,20,,20,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",FALSE,TRUE,TRUE,FALSE,1396,1236,1068,TEST
456,4423,4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),Nd:YAG laser (group B),continuous,,,20,,20,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",FALSE,TRUE,TRUE,FALSE,1396,1236,1068,TEST
457,4424,4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),CPP-ACP crème (group C),continuous,,,20,,20,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",FALSE,TRUE,TRUE,FALSE,1396,1236,1068,TEST
458,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Distilled and deionized water (group A),continuous,,,20,,20,,,,All numerical values are in a graphical format of table.,FALSE,TRUE,TRUE,FALSE,1396,1236,1068,TEST
459,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Nd:YAG laser (group B),continuous,,,20,,20,,,,All numerical values are in a graphical format of table.,FALSE,TRUE,TRUE,FALSE,1396,1236,1068,TEST
460,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),CPP-ACP crème (group C),continuous,,,20,,20,,,,All numerical values are in a graphical format of table.,FALSE,TRUE,TRUE,FALSE,1396,1236,1068,TEST
461,4430,5726464,25(OH)D levels,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
462,4431,5726464,Lipid profile: total cholesterol,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
463,4431,5726464,Lipid profile: HDL-c,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
464,4431,5726464,Lipid profile: LDL-c,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
465,4431,5726464,Lipid profile: Triglycerides,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
466,4433,5726464,Changes in body mass index,Vitamin D plus calcium supplementation,Placebo,continuous,,79,,86,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,6563,4244,3133,TEST
467,4434,5726464,Metabolic syndrome,Vitamin D plus calcium supplementation,Placebo,binary,9,66,11,75,,,,,,FALSE,TRUE,FALSE,TRUE,6563,4244,3133,TEST
468,4802,5515881,memory score,demanding balance training program,relaxation group,continuous,,,,,9.44,5.48,8,4.16,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,4475,3500,2868,TEST
469,4799,5515881,dynamic balance performance on the stability platform,demanding balance training program,relaxation group,continuous,,,,,7.54,2.57,6.29,1.84,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,4475,3500,2868,TEST
470,4800,5515881,center of pressure (CoP) sway velocity,demanding balance training program,relaxation group,continuous,,,,,0.63,0.11,0.67,0.18,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,4475,3500,2868,TEST
471,4803,5515881,spatial score,demanding balance training program,relaxation group,continuous,,,,,0.443,0.75,0.04,0.91,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,4475,3500,2868,TEST
472,5710,3343759,improvment in ANELT by day 21,higher level of education (>12 years),<12 years of education,continuous,,,,,,,,,Median is reported. Group sizes are only available in methods section.,FALSE,TRUE,FALSE,FALSE,3838,2633,2065,TEST
473,5711,3343759,aphasia types,very early speech and language therapy (SLT),control,binary,,,,,,,,,Numerical data is in figure and group sizes are not available in abstract or results sections.,TRUE,FALSE,FALSE,FALSE,3838,2633,2065,TEST
474,5522,4144850,Independent household latrines number,Total Sanitation Campaign,Control,binary,673,"1,525",366,"1,514",,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
475,5523,4144850,Open defecation - adult men,Total Sanitation Campaign,Control,binary,1138,"1,525",1273,"1,514",,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
476,5523,4144850,Open defecation - adult women,Total Sanitation Campaign,Control,binary,1116,"1,525",1264,"1,514",,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
477,5523,4144850,Open defecation - children,Total Sanitation Campaign,Control,binary,1279,"1,525",1350,"1,514",,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
478,5525,4144850,Helminth infections,Total Sanitation Campaign,Control,binary,34,581,32,569,,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
479,5526,4144850,Anemia,Total Sanitation Campaign,Control,binary,"1,078","1,919",976,"1,922",,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
480,4801,5515881,VO2peak,demanding balance training program,relaxation group,continuous,,,,,32.07,6.52,31.947,7.89,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,4475,3500,2868,TEST
481,5521,4144850,Sanitation facility improvement,Total Sanitation Campaign,Control,binary,630,"1,522",342,"1,512",,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
482,5524,4144850,E. coli contaminated water,Total Sanitation Campaign,Control,binary,310,404,331,403,,,,,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,24614,13328,9179,TEST
483,5712,3343759,Amsterdam-Nijmegen everyday language test (ANELT),very early speech and language therapy (SLT),control,continuous,,59,,55,,,,,"Median values are reported. Group size is based on ANELT by day 21, intent-to-treat.",FALSE,TRUE,FALSE,FALSE,3838,2633,2065,TEST
484,5713,3343759,history of myocardial infarction,very early speech and language therapy (SLT),control,binary,,,,,,,,,Numerical data are only in methods section.,FALSE,TRUE,FALSE,FALSE,3838,2633,2065,TEST
485,5714,3343759,communication ability,very early speech and language therapy (SLT),control,continuous,,,,,,,,,Unclear outcome.,FALSE,FALSE,FALSE,FALSE,3838,2633,2065,TEST
486,6382,3786549,Improvement in Vaginal Maturation Index,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44,,44,35.2,21.7,9.9,14.5,Numerical values based on intention-to-treat,FALSE,TRUE,FALSE,TRUE,9725,6231,4323,TEST
487,6383,3786549,Baseline characteristics: menopause,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44,,44,13.11,7.02,13,6.94,,FALSE,TRUE,FALSE,TRUE,9725,6231,4323,TEST
488,6383,3786549,Baseline characteristics: height,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44,,44,154.86,5.45,153.43,5.88,,FALSE,TRUE,FALSE,TRUE,9725,6231,4323,TEST
489,6383,3786549,Baseline characteristics: weight,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44,,44,56.16,8.1,57.82,8.24,,FALSE,TRUE,FALSE,TRUE,9725,6231,4323,TEST
490,6383,3786549,Baseline characteristics: deliveries,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44,,44,2.14,1.76,2.64,1.79,,FALSE,TRUE,FALSE,TRUE,9725,6231,4323,TEST
491,6484,5419060,Sample rejection rate: CHC A,Phlebotomy training programme,Control,binary,79,10218,60,7557,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
492,6484,5419060,Sample rejection rate: CHC B,Phlebotomy training programme,Control,binary,48,4114,45,3973,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
493,6484,5419060,Sample rejection rate: CDC C,Phlebotomy training programme,Control,binary,37,2279,38,2321,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
494,6484,5419060,Sample rejection rate: CDC D,Phlebotomy training programme,Control,binary,7,630,8,589,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
495,6488,5419060,Request-form errors: CHC A,Phlebotomy training programme,Control,binary,8,10218,11,7557,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
496,6488,5419060,Request-form errors: CHC B,Phlebotomy training programme,Control,binary,12,4114,11,3973,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
497,6488,5419060,Request-form errors: CDC C,Phlebotomy training programme,Control,binary,6,2279,3,2321,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
498,6488,5419060,Request-form errors: CDC D,Phlebotomy training programme,Control,binary,0,630,0,589,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
499,6489,5419060,Preanalytical errors: CHC A,Phlebotomy training programme,Control,binary,27,10218,17,7557,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
500,6489,5419060,Preanalytical errors: CHC B,Phlebotomy training programme,Control,binary,12,4114,10,3973,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
501,6489,5419060,Preanalytical errors: CDC C,Phlebotomy training programme,Control,binary,10,2279,15,2321,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
502,6489,5419060,Preanalytical errors: CDC D,Phlebotomy training programme,Control,binary,2,630,4,589,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
503,6485,5419060,Phlebotomy questionnaire score: CHC A,Phlebotomy training programme,Control,continuous,,23,,23,96,3.89,63,12.31,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,9292,5719,4155,TEST
504,6485,5419060,Phlebotomy questionnaire score: CHC B,Phlebotomy training programme,Control,continuous,,23,,23,93,1.37,58,7.12,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,9292,5719,4155,TEST
505,6485,5419060,Phlebotomy questionnaire score: CDC C,Phlebotomy training programme,Control,continuous,,23,,23,97,3.85,60,5.25,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,9292,5719,4155,TEST
506,6485,5419060,Phlebotomy questionnaire score: CDC D,Phlebotomy training programme,Control,continuous,,23,,23,97,1.21,63,4.31,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,9292,5719,4155,TEST
507,6486,5419060,Techinque related rejections: CHC A,Phlebotomy training programme,Control,binary,20,10218,20,7557,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
508,6486,5419060,Techinque related rejections: CHC B,Phlebotomy training programme,Control,binary,15,4114,8,3973,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
509,6486,5419060,Techinque related rejections: CDC C,Phlebotomy training programme,Control,binary,18,2279,15,2321,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
510,6486,5419060,Techinque related rejections: CDC D,Phlebotomy training programme,Control,binary,2,630,4,589,,,,,,FALSE,TRUE,FALSE,TRUE,9292,5719,4155,TEST
511,6550,4033571,Overall seizure median percent improvement,Extended-release oxcarbazepine 2400 mg,Control,continuous,,111,,117,-42.9,,-28.7,,SD was not given,FALSE,FALSE,FALSE,FALSE,8206,5593,4514,TEST
512,6553,4033571,Adverse effects,Extended-release oxcarbazepine 1200 mg,Control,binary,69,123,67,122,,,,,,FALSE,TRUE,FALSE,TRUE,8206,5593,4514,TEST
513,6549,4033571,Overall seizure median percent reduction,Extended-release oxcarbazepine 1200 mg,Control,continuous,,109,,117,-38.3,,-28.7,,SD was not given,FALSE,FALSE,FALSE,FALSE,8206,5593,4514,TEST
514,6551,4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 1200 mg,Control,continuous,,,,,-34.5,,-13.3,,"Group sizes are only in figure, and SD is not available.",TRUE,FALSE,FALSE,FALSE,8206,5593,4514,TEST
515,6552,4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 2400 mg,Control,continuous,,,,,-52.7,,-13.3,,"Group sizes are only in figure, and SD is not available.",TRUE,FALSE,FALSE,FALSE,8206,5593,4514,TEST
516,6554,4033571,Adverse effects,Extended-release oxcarbazepine 2400 mg,Control,binary,85,123,67,121,,,,,,FALSE,TRUE,FALSE,TRUE,8206,5593,4514,TEST
517,6695,5154016,24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30,,32,187.9,82,230.8,75,,FALSE,TRUE,FALSE,TRUE,3046,2156,1642,TEST
518,6699,5154016,Second 24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30,,30,53.7,3.8,63.5,14.2,,FALSE,TRUE,FALSE,TRUE,3046,2156,1642,TEST
519,6700,5154016,Second 24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30,,30,63.3,8.9,63.5,14.2,,FALSE,TRUE,FALSE,TRUE,3046,2156,1642,TEST
520,6696,5154016,24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30,,30,185.2,68,230.8,75,,FALSE,TRUE,FALSE,TRUE,3046,2156,1642,TEST
521,6697,5154016,Total drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30,,30,231.5,18.1,318.5,26.7,,FALSE,TRUE,FALSE,TRUE,3046,2156,1642,TEST
522,6698,5154016,Total drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30,,30,248.5,18.8,318.5,26.7,,FALSE,TRUE,FALSE,TRUE,3046,2156,1642,TEST
523,6741,5325897,First test results,Evaluation with feedback,Evaluation without feedback,continuous,,15,,15,10.24,0.77,9.73,0.77,,FALSE,FALSE,FALSE,TRUE,4260,2410,1703,TEST
524,6741,5325897,Second test results,Evaluation with feedback,Evaluation without feedback,continuous,,15,,15,17.73,0.46,12.13,0.47,,FALSE,FALSE,FALSE,TRUE,4260,2410,1703,TEST
525,6742,5325897,Final test results,Evaluation with feedback,Evaluation without feedback,continuous,,15,,15,18.53,0.22,18.99,0.22,,FALSE,FALSE,FALSE,TRUE,4260,2410,1703,TEST
526,6916,4411165,tympanic temperature from Pre to P20 (-0.28 ±0.11°C),"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10,,10,-0.28,0.11,-0.14,0.05,Values on mean change are based on what is reported in abstract. ,TRUE,FALSE,FALSE,TRUE,3146,2589,2336,TEST
527,6918,4411165,systolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10,,10,,,,,Numerical values are only in the figures.,TRUE,FALSE,FALSE,FALSE,3146,2589,2336,TEST
528,6919,4411165,diastolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10,,10,,,,,Numerical values are only in the figures.,TRUE,FALSE,FALSE,FALSE,3146,2589,2336,TEST
529,6915,4411165,effects of cryostimulation on the ANS - heart rate,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10,,10,-7.7,2.3,-5.02,1.07,"Changed from original outcome but adding ""- heart rate"" to make it more specific. Numbers are mean change.",TRUE,FALSE,FALSE,TRUE,3146,2589,2336,TEST
530,6917,4411165,Tskin of the head,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10,,10,,,,,Numerical values are only in the figures.,TRUE,FALSE,FALSE,FALSE,3146,2589,2336,TEST
531,7830,4230312,improvement of disorder,quetiapine 600 mg/day,placebo,continuous,,289,,204,-14.88,10.54,-11.61,10.12,Back calculated SD from SE.,TRUE,FALSE,FALSE,TRUE,6201,5058,3918,TEST
532,7829,4230312,improvement of disorder,quetiapine 300 mg/day,placebo,continuous,,283,,204,-15.58,10.43,-11.61,10.12,Back calculated SD from SE.,TRUE,FALSE,FALSE,TRUE,6201,5058,3918,TEST
533,8166,5800236,Months of sick leave,Nacadia® nature-based therapy,Cognitive behavioral therapy,continuous,,37,,35,,,,,Numerical values were not given for this outcome.,TRUE,FALSE,FALSE,FALSE,4517,2571,1980,TEST
534,7794,3508963,Pain relief,Intravenous lidocaine,Intravenous morphine,continuous,,120,,120,1.13,1.15,2.23,1.57,Values from 30 minutes.,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
535,7793,3508963,Response to treatment,Intravenous lidocaine,Intravenous morphine,binary,108,120,84,120,,,,,,FALSE,FALSE,FALSE,TRUE,3561,2387,1552,TEST
536,7795,3508963,Baseline characteristics - age,Intravenous lidocaine,Intravenous morphine,continuous,,120,,120,35.23,12.37,37.71,11.08,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
537,7795,3508963,Baseline characteristics - hydronephrosis in left kidney,Intravenous lidocaine,Intravenous morphine,binary,52,120,52,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
538,7795,3508963,Baseline characteristics - hydronephrosis in right kidney,Intravenous lidocaine,Intravenous morphine,binary,57,120,53,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
539,7795,3508963,Baseline characteristics - did not have hydronephrosis,Intravenous lidocaine,Intravenous morphine,binary,11,120,15,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
540,7795,3508963,Baseline characteristics - history of reurrent stone,Intravenous lidocaine,Intravenous morphine,binary,49,120,64,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
541,7795,3508963,Baseline characteristics - history of first stone,Intravenous lidocaine,Intravenous morphine,binary,70,120,56,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
542,7795,3508963,Baseline characteristics - right kidney stone,Intravenous lidocaine,Intravenous morphine,binary,60,120,57,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
543,7795,3508963,Baseline characteristics - left kidney stone,Intravenous lidocaine,Intravenous morphine,binary,60,120,63,120,,,,,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
544,7792,3508963,Pain score after 5 minutes,Intravenous lidocaine,Intravenous morphine,continuous,,120,,120,3.18,2.27,4.45,2.16,,FALSE,TRUE,FALSE,TRUE,3561,2387,1552,TEST
545,8460,3263860,HbA1c reduction,Real-Time Continuous Glucose Monitoring,Control,continuous,,69,,68,-0.1,0.6,-0.1,0.6,Mean change,FALSE,TRUE,TRUE,TRUE,3178,2587,2232,TEST
546,8461,3263860,Severe hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,binary,3,73,5,71,,,,,,FALSE,TRUE,TRUE,TRUE,3178,2587,2232,TEST
547,8463,3263860,Serious skin reactions,Real-Time Continuous Glucose Monitoring,Control,binary,0,69,0,68,,,,,Unclear group sizes. Used the group size for 26-week visit.,FALSE,FALSE,TRUE,TRUE,3178,2587,2232,TEST
548,8462,3263860,Diabetic ketoacidosis,Real-Time Continuous Glucose Monitoring,Control,binary,0,69,0,68,,,,,Unclear group sizes. Used the group size for 26-week visit.,FALSE,FALSE,TRUE,TRUE,3178,2587,2232,TEST
549,8464,3263860,PAID questionnaire fear of hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,continuous,,69,,68,,,,,Numerical values in Table which is a graphic,FALSE,TRUE,TRUE,FALSE,3178,2587,2232,TEST
550,9719,3648394,LF:HF component of HRV,10-week yoga program,Control,continuous,,18,,19,0.35,0.43,0.04,0.38,Numerical values are from Week 11.,FALSE,TRUE,FALSE,TRUE,9556,6245,4261,TEST
551,9724,3648394,Push-up test,10-week yoga program,Control,continuous,,18,,19,21,11,20,13,Numerical values are from Week 11.,FALSE,TRUE,FALSE,TRUE,9556,6245,4261,TEST
552,9725,3648394,Quality of life - PCS (SF36),10-week yoga program,Control,continuous,,18,,19,47.5,2.7,46.9,4.8,"Original outcome was just ""Quality of Life"". Numerical values are from Week 11.",FALSE,TRUE,FALSE,TRUE,9556,6245,4261,TEST
553,9725,3648394,Quality of life - MCS (SF36),10-week yoga program,Control,continuous,,18,,19,47.5,10.6,48.5,7.7,"Original outcome was just ""Quality of Life"". Numerical values are from Week 11.",FALSE,TRUE,FALSE,TRUE,9556,6245,4261,TEST
554,9720,3648394,pNN50,10-week yoga program,Control,continuous,,18,,19,20.7,25.3,19.4,18.4,Numerical values are from Week 11.,FALSE,TRUE,FALSE,TRUE,9556,6245,4261,TEST
555,9721,3648394,Flexibility,10-week yoga program,Control,continuous,,18,,19,31,8.7,26.4,10.4,Numerical values are from Week 11 data for sit and reach test.,FALSE,TRUE,FALSE,TRUE,9556,6245,4261,TEST
556,9828,3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Control,continuous,,12,,16,-17.1,68.08,-19.57,93.53,From per protocol,FALSE,TRUE,FALSE,TRUE,6022,3786,2937,TEST
557,9830,3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Casein shake (Placebo),continuous,,12,,16,-17.1,68.08,-19.57,93.53,From per protocol,FALSE,TRUE,FALSE,TRUE,6022,3786,2937,TEST
558,9831,3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Control,continuous,,12,,16,-4,12.35,-8,65.41,From per protocol,FALSE,TRUE,FALSE,TRUE,6022,3786,2937,TEST
559,9833,3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Casein shake (Placebo),continuous,,12,,16,-4,12.35,-8,65.41,From per protocol,FALSE,TRUE,FALSE,TRUE,6022,3786,2937,TEST
560,9834,3496170,Learned irrelevance index,Biperiden,Placebo,continuous,,15,,15,,,,,numerical data in figure.,TRUE,FALSE,TRUE,FALSE,2318,1990,1731,TEST
561,9835,3496170,P3a amplitude,Biperiden,Placebo,continuous,,15,,15,,,,,numerical data in figure.,TRUE,FALSE,TRUE,FALSE,2318,1990,1731,TEST
562,9836,3496170,P3a latency,Biperiden,Placebo,continuous,,15,,15,,,,,numerical data in figure.,TRUE,FALSE,TRUE,FALSE,2318,1990,1731,TEST
563,9837,3496170,Self-report questionnaire,Biperiden,Placebo,continuous,,15,,15,,,,,No numerical values are given.,FALSE,FALSE,TRUE,FALSE,2318,1990,1731,TEST
564,9838,3496170,N1 latency,Biperiden,Placebo,continuous,,15,,15,,,,,numerical data in figure.,TRUE,FALSE,TRUE,FALSE,2318,1990,1731,TEST
565,9839,3496170,N1 amplitude,Biperiden,Placebo,continuous,,15,,15,,,,,numerical data in figure.,TRUE,FALSE,TRUE,FALSE,2318,1990,1731,TEST
566,8556,5541727,Knee Injury and Osteoarthritis Outcome Score improvement,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,6118,5345,4032,TEST
567,8560,5541727,Tibial bone expansion,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,-0.7,1.5,1,1.1,"Values are from ""total tibial plateau"" for 24 months",FALSE,TRUE,FALSE,TRUE,6118,5345,4032,TEST
568,8555,5541727,Treatment-related serious adverse events,Allogeneic mesenchymal precursor cells,Control,binary,0,11,0,6,,,,,,FALSE,FALSE,FALSE,TRUE,6118,5345,4032,TEST
569,8557,5541727,Activities of daily living,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,6118,5345,4032,TEST
570,8558,5541727,Symptom improvement,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,6118,5345,4032,TEST
571,8559,5541727,SF-36 bodily pain score improvement,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,6118,5345,4032,TEST
572,8561,5541727,medial tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,-1.4,4.2,-3.3,5.3,Values are from 24 months,FALSE,TRUE,FALSE,TRUE,6118,5345,4032,TEST
573,8561,5541727,lateral tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,continuous,,11,,6,-3.7,3.4,-0.8,3.5,Values are from 24 months,FALSE,TRUE,FALSE,TRUE,6118,5345,4032,TEST
574,8565,2952311,Verbal rating scale pain intensity,Acupressure at distal points,Control,continuous,,11,,11,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,3603,2475,2143,TEST
575,8562,2952311,Verbal rating scale pain intensity,Acupressure at local points,Control,continuous,,11,,11,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,3603,2475,2143,TEST
576,8563,2952311,State-Trait Anxiety Inventory-I,Acupressure at local points,Control,continuous,,11,,11,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,3603,2475,2143,TEST
577,8567,2952311,Salivary alpha-amylase,Acupressure at distal points,Acupressure at local points,continuous,,11,,11,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,3603,2475,2143,TEST
578,8564,2952311,Muscle hardness,Acupressure at local points,Control,continuous,,11,,11,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,3603,2475,2143,TEST
579,8566,2952311,State-Trait Anxiety Inventory-I,Acupressure at distal points,Control,continuous,,11,,11,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,3603,2475,2143,TEST
580,10217,3504298,Anxious symptoms,Face-based attentional bias modification,Placebo,continuous,,16,,14,,,,,"F-values given, cant use for point estimates, and values in figure",TRUE,FALSE,FALSE,FALSE,4963,4205,3331,TEST
581,11584,115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
582,10219,3504298,Attentional Function,Word-based attentional bias modification,Face-based attentional bias modification,continuous,,16,,16,,,,,"F-values given, cant use for point estimates, and values in figure",TRUE,FALSE,FALSE,FALSE,4963,4205,3331,TEST
583,10218,3504298,Difference of cortisol on waking and the highest level of following samples,Word-based attentional bias modification,Placebo,continuous,,16,,15,,,,,"F-values given, cant use for point estimates, and values in figure",TRUE,FALSE,FALSE,FALSE,4963,4205,3331,TEST
584,10215,3504298,Depressive symptoms,Face-based attentional bias modification,Placebo,continuous,,16,,14,,,,,"F-values given, cant use for point estimates",FALSE,FALSE,FALSE,FALSE,4963,4205,3331,TEST
585,10216,3504298,Depressive symptoms,Word-based attentional bias modification,Placebo,continuous,,16,,15,,,,,"F-values given, cant use for point estimates",FALSE,FALSE,FALSE,FALSE,4963,4205,3331,TEST
586,11522,547916,matrix metalloproteinase-9 (MMP-9),doxycycline (100 mg),placebo,continuous,,10,,4,2.18,1.94,3.26,3.58,found in abstract,FALSE,FALSE,FALSE,TRUE,4542,3636,2822,TEST
587,11581,115849,patients discontinued due to lack of efficacy,etoricoxib 90 mg once daily,placebo,binary,44,353,90,357,,,,,found in fig 1,TRUE,FALSE,FALSE,TRUE,6464,5362,4091,TEST
588,11581,115849,patients discontinued due to lack of efficacy,naproxen 500 mg twice daily,placebo,binary,19,181,90,357,,,,,found in fig 1,TRUE,FALSE,FALSE,TRUE,6464,5362,4091,TEST
589,11583,115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
590,11583,115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
591,11583,115849,Tender joint count,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
592,11583,115849,Swollen joint count,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
593,11583,115849,Patient global assessment of pain,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
594,11583,115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
595,11583,115849,Serum C-reactive protein,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
596,11583,115849,ACR20 responder criteria,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
597,11583,115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,placebo,continuous,,353,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
598,11583,115849,Patient global assessment of disease activity,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
599,11583,115849,investigator global assessment of disease activity,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
600,11583,115849,Tender joint count,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
601,11583,115849,Swollen joint count,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
602,11583,115849,Patient global assessment of pain,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
603,11583,115849,Health Assessment Questionnaire disability,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
604,11583,115849,Serum C-reactive protein,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
605,11583,115849,ACR20 responder criteria,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
606,11583,115849,Discontinuation due to lack of efficacy,naproxen 500 mg twice daily,placebo,continuous,,181,,357,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
607,11584,115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
608,11584,115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
609,11584,115849,Tender joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
610,11584,115849,Swollen joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
611,11584,115849,Patient global assessment of pain,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
612,11584,115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
613,11584,115849,Serum C-reactive protein,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
614,11584,115849,ACR20 responder criteria,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353,,181,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,6464,5362,4091,TEST
615,11602,1863515,haemoglobin level between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,754,,656,-0.4,,0,,"given as estimated change and no std given, also in figure and graphic format",TRUE,TRUE,TRUE,FALSE,3963,3457,3103,TEST
616,11602,1863515,leucocyte count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,754,,656,-423,,0,,"given as estimated change and no std given, also in figure and graphic format",TRUE,TRUE,TRUE,FALSE,3963,3457,3103,TEST
617,11602,1863515,absolute neutrophil count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,754,,656,-485,,0,,"given as estimated change and no std given, also in figure and graphic format",TRUE,TRUE,TRUE,FALSE,3963,3457,3103,TEST
618,11603,1863515,haemoglobin level at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,754,,656,10.7,,11.2,,"means given but no std given, tables and figures in graphic format",TRUE,TRUE,TRUE,FALSE,3963,3457,3103,TEST
619,11603,1863515,leucocyte count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,754,,656,8818,,8362,,"means given but no std given, tables and figures in graphic format",TRUE,TRUE,TRUE,FALSE,3963,3457,3103,TEST
620,11603,1863515,absolute neutrophil count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,754,,656,5639,,6150,,"means given but no std given, tables and figures in graphic format",TRUE,TRUE,TRUE,FALSE,3963,3457,3103,TEST
621,11904,3493722,eradication rate of H. pylori in ITT,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,71,85,72,84,,,,,"found in abstract and table, assumed binary because given as percentage of population",FALSE,FALSE,FALSE,TRUE,1684,1549,1357,TEST
622,11904,3493722,eradication rate of H. pylori in PP,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,71,81,72,81,,,,,"found in abstract and table, assumed binary because given as percentage of population",FALSE,FALSE,FALSE,TRUE,1684,1549,1357,TEST
623,11905,3493722,side effects,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,19,85,32,84,,,,,found in results section,FALSE,FALSE,FALSE,TRUE,1684,1549,1357,TEST
624,11906,3493722,good compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,74,,74,,,,,,"found in table 2, assumed binary because proportion of whole given",FALSE,TRUE,TRUE,FALSE,1684,1549,1357,TEST
625,11906,3493722,well compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,8,,4,,,,,,"found in table 2, assumed binary because proportion of whole given",FALSE,TRUE,TRUE,FALSE,1684,1549,1357,TEST
626,11906,3493722,poor compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,2,,3,,,,,,"found in table 2, assumed binary because proportion of whole given",FALSE,TRUE,TRUE,FALSE,1684,1549,1357,TEST
627,12232,3510731,Clicked on Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,binary,247,6051,515,5892,,,,,found in table 1,FALSE,TRUE,FALSE,TRUE,1665,1296,943,TEST
628,12233,3510731,Clicked on Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,binary,202,6051,362,5892,,,,,found in table 1,FALSE,TRUE,FALSE,TRUE,1665,1296,943,TEST
629,12234,3510731,Median time in seconds (interquartile range) - Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,continuous,,6051,,5892,25,,25.3,,"found in table 1, IQ range given rather and std",FALSE,TRUE,FALSE,FALSE,1665,1296,943,TEST
630,12235,3510731,Median time in seconds (interquartile range) - Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,continuous,,6051,,5892,3.5,,3.6,,"found in table 1, IQ range given rather and std",FALSE,TRUE,FALSE,FALSE,1665,1296,943,TEST
631,12275,3936115,The number of diverticulitis clinical symptom occurrences during 12months,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,2,30,7,22,,,,,found in table 1,FALSE,TRUE,FALSE,TRUE,2217,2016,1562,TEST
632,12276,3936115,the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,1,30,5,22,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,2217,2016,1562,TEST
633,12277,3936115,"Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): ""Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12 months?""",Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,17,30,5,22,,,,,found in table 3,FALSE,TRUE,FALSE,TRUE,2217,2016,1562,TEST
634,12289,5777645,HbA1c levels,to peer-led structured patient education,conventional care alone,continuous,,70,,70,1.05,2,0.15,1.7,SDs found in abstract while group sizes and means found in table 2,FALSE,TRUE,FALSE,TRUE,8661,5060,3738,TEST
635,12290,5777645,Mean BMI change,to peer-led structured patient education,conventional care alone,continuous,,,,,-1.65,2.5,0.05,3.2,SDs found in abstract while group sizes and means found in table 2,FALSE,TRUE,FALSE,TRUE,8661,5060,3738,TEST
636,12291,5777645,Mean waist circumference,to peer-led structured patient education,conventional care alone,continuous,,,,,-3.34,9.3,2.65,10.3,SDs found in abstract while group sizes and means found in table 2,FALSE,TRUE,FALSE,TRUE,8661,5060,3738,TEST
637,12720,4132222,decrease in average lesion,application of a canola phenolic acid-based cream (CPA),placebo,continuous,,30,,15,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,2177,1885,1617,TEST
638,12721,4132222,"higher prevalence of lesion scabbing, a sign of healing",application of a canola phenolic acid-based cream (CPA),placebo,continuous,,30,,15,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,2177,1885,1617,TEST
639,12772,4511433,LDL cholesterol,5 mg elobixibat,placebo,continuous,,12,,12,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,4648,3874,2969,TEST
640,12772,4511433,LDL cholesterol,2.5 mg,placebo,continuous,,12,,12,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,4648,3874,2969,TEST
641,12879,5830087,objective response rate (ORR),"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),binary,29,48,10,23,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,11942,10628,8141,TEST
642,12880,5830087,disease control rate,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),binary,45,48,21,23,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,11942,10628,8141,TEST
643,12880,5830087,duration of objective response,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),continuous,,48,,23,,,,,"given as median with confidence interval, cannot calculate",FALSE,TRUE,FALSE,FALSE,11942,10628,8141,TEST
644,12880,5830087,progression-free survival,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),continuous,,48,,23,,,,,"given as median with confidence interval, cannot calculate",FALSE,TRUE,FALSE,FALSE,11942,10628,8141,TEST
645,13025,4675066,The mean cognitive score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27,,26,99.4,12.2,101.7,8.2,found in table 2,FALSE,TRUE,FALSE,TRUE,6682,5735,4224,TEST
646,13025,4675066,The mean language score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27,,26,97.2,12.2,97.9,11.5,found in table 2,FALSE,TRUE,FALSE,TRUE,6682,5735,4224,TEST
647,13025,4675066,The mean motor score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27,,26,93.9,10.8,92.4,9.7,found in table 2,FALSE,TRUE,FALSE,TRUE,6682,5735,4224,TEST
648,13097,5976307,induction time,etomidate,propofol based on midazolam,continuous,,,,,,,,,found in table 2,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
649,13097,5976307,total procedure time,etomidate,propofol based on midazolam,continuous,,,,,,,,,found in table 2,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
650,13097,5976307,awake time,etomidate,propofol based on midazolam,continuous,,,,,,,,,found in table 2,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
651,13098,5976307,The incidence rate of all cardiopulmonary adverse events,etomidate,propofol based on midazolam,binary,,,,,,,,,found in table 3,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
652,13099,5976307,The incidence rate of vital sign fluctuation (VSF),etomidate,propofol based on midazolam,binary,,,,,,,,,found in table 3,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
653,13100,5976307,the incidence rate of adverse events disturbing the procedure,etomidate,propofol based on midazolam,binary,,,,,,,,,found in table 3,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
654,13101,5976307,The incidence rate of myoclonus,etomidate,propofol based on midazolam,binary,,,,,,,,,found in table 3,FALSE,TRUE,TRUE,FALSE,2560,2044,1751,TEST
655,13175,5773985,mean volume of both the solutions used,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,,,,4.15,0.52,4.12,0.6,Found in abstract and results,FALSE,FALSE,FALSE,FALSE,2609,2261,1917,TEST
656,13176,5773985,subjective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,,,,3,1.08,2.92,1.03,Found in abstract and results,FALSE,FALSE,FALSE,FALSE,2609,2261,1917,TEST
657,13176,5773985,objective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,,,,7.4,1.93,7.28,1.59,Found in abstract and results,FALSE,FALSE,FALSE,FALSE,2609,2261,1917,TEST
658,13177,5773985,duration of surgical procedure,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,,,,,,,,Graphic format table,FALSE,TRUE,TRUE,FALSE,2609,2261,1917,TEST
659,13178,5773985,the mean duration of postoperative analgesia,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,,,,508.92,63.3,1840.84,819.51,Found in abstract and results,FALSE,FALSE,FALSE,FALSE,2609,2261,1917,TEST
660,13179,5773985,number of analgesic tablets,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,,,,,,,,Graphic format table,FALSE,TRUE,TRUE,FALSE,2609,2261,1917,TEST
661,13216,4458006,amplitude of whisking,facial nerve transection and subsequent repair either at the main trunk of the nerve (group 1),"2 cm distally, at the main bifurcation (group 2)",continuous,,12,,12,17.2,,6.9,,No std given,FALSE,FALSE,FALSE,FALSE,1302,1180,1009,TEST
662,13294,4987981,"Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores",metformin or pioglitazone,placebo,continuous,,37,,23,,,,,Values combined and given in figure,TRUE,FALSE,FALSE,FALSE,9637,7894,5779,TEST
663,13295,4987981,percentage of patients achieving 75 % reduction in PASI and ESI scores,metformin or pioglitazone,placebo,continuous,,37,,23,,,,,Values combined and given in figure,TRUE,FALSE,FALSE,FALSE,9637,7894,5779,TEST
664,13296,4987981,FPG,metformin,placebo,continuous,,21,,23,101.9,35.1,97.6,20.8,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,9637,7894,5779,TEST
665,13296,4987981,FPG,pioglitazone,placebo,continuous,,16,,23,103.4,28.9,97.6,20.8,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,9637,7894,5779,TEST
666,13296,4987981,total cholesterol,metformin,placebo,continuous,,21,,23,206.9,36.2,184.4,37.5,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,9637,7894,5779,TEST
667,13296,4987981,total cholesterol,pioglitazone,placebo,continuous,,16,,23,207.2,42.3,184.4,37.5,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,9637,7894,5779,TEST
668,13296,4987981,triglycerides levels,metformin,placebo,continuous,,21,,23,194.3,63.1,181.8,61.3,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,9637,7894,5779,TEST
669,13296,4987981,triglycerides levels,pioglitazone,placebo,continuous,,16,,23,200.1,55.9,181.8,61.3,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,9637,7894,5779,TEST
670,13297,4987981,IL-6 and TNF-α levels,metformin or pioglitazone,placebo,continuous,,37,,23,,,,,Values combined and given in figure,TRUE,FALSE,FALSE,FALSE,9637,7894,5779,TEST
671,13313,4550271,Community knowledge,provider,control,continuous,,14,,12,,,,,outcome too broad,FALSE,TRUE,FALSE,FALSE,24886,12978,8556,TEST
672,13313,4550271,Community knowledge,provider-school intervention,control,continuous,,14,,12,,,,,outcome too broad,FALSE,TRUE,FALSE,FALSE,24886,12978,8556,TEST
673,13314,4550271,treatment according to guidelines,provider,control,continuous,,14,,12,36.4,32,22.6,23,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,24886,12978,8556,TEST
674,13314,4550271,treatment according to guidelines,provider-school intervention,control,continuous,,14,,12,23.5,26,22.6,23,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,24886,12978,8556,TEST
675,13315,4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider,control,continuous,,14,,12,56.1,31,64.2,28,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,24886,12978,8556,TEST
676,13315,4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider-school intervention,control,continuous,,14,,12,56.4,33,64.2,28,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,24886,12978,8556,TEST
677,13505,5777419,the total cultivable microbiota,probiotic,placebo,continuous,,16,,15,,,,,median and IQ scores given,FALSE,TRUE,FALSE,FALSE,9410,4699,3181,TEST
678,13505,5777419,the total cultivable microbiota,antibiotic,placebo,continuous,,16,,15,,,,,median and IQ scores given,FALSE,TRUE,FALSE,FALSE,9410,4699,3181,TEST
679,13506,5777419,attachment gain,probiotic,placebo,continuous,,16,,15,3.4,0.6,4.3,1.4,found in table 2,FALSE,TRUE,FALSE,TRUE,9410,4699,3181,TEST
680,13506,5777419,reduction of PPD,probiotic,placebo,continuous,,16,,15,2.2,0.3,2.5,0.6,found in table 2,FALSE,TRUE,FALSE,TRUE,9410,4699,3181,TEST
681,13506,5777419,reduction of plaque,probiotic,placebo,continuous,,16,,15,28.1,14.6,27.4,13,found in table 2,FALSE,TRUE,FALSE,TRUE,9410,4699,3181,TEST
682,13506,5777419,attachment gain,antibiotic,placebo,continuous,,16,,15,4.1,1,4.3,1.4,found in table 2,FALSE,TRUE,FALSE,TRUE,9410,4699,3181,TEST
683,13506,5777419,reduction of PPD,antibiotic,placebo,continuous,,16,,15,2.3,0.3,2.5,0.6,found in table 2,FALSE,TRUE,FALSE,TRUE,9410,4699,3181,TEST
684,13506,5777419,reduction of plaque,antibiotic,placebo,continuous,,16,,15,31.8,14.8,27.4,13,found in table 2,FALSE,TRUE,FALSE,TRUE,9410,4699,3181,TEST
685,13760,2836833,Fecal fat loss,1500 mg calcium,500 mg calcium,continuous,,17,,17,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,12992,7163,5694,TEST
686,13761,2836833,Urinary calcium excretion,1500 mg calcium,500 mg calcium,continuous,,17,,17,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,12992,7163,5694,TEST
687,13762,2836833,weight loss,1500 mg calcium,500 mg calcium,continuous,,17,,17,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,12992,7163,5694,TEST
688,13763,2836833,systolic or diastolic blood pressure,1500 mg calcium,500 mg calcium,continuous,,17,,17,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,12992,7163,5694,TEST
689,13830,4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),no further reminder (IG1),binary,94,102,84,104,,,,,found in text as fractions of group sizes,FALSE,FALSE,FALSE,TRUE,10493,8112,5695,TEST
690,13830,4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),reminder card together with the appointment letter (IG2),binary,94,102,91,107,,,,,found in text as fractions of group sizes,FALSE,FALSE,FALSE,TRUE,10493,8112,5695,TEST
691,13831,4210722,use of a reminder card,a separate reminder card 4 days before the appointment (IG3); reminder card together with the appointment letter (IG2);,no further reminder (IG1),binary,185,209,84,104,,,,,found in text as fractions of group sizes,FALSE,FALSE,FALSE,TRUE,10493,8112,5695,TEST
692,5635,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Duloxetine (D),continuous,,30,,30,,,,,found in fig2,TRUE,FALSE,FALSE,FALSE,6401,5359,3891,TEST
693,5636,5712123,postoperative pain at rest,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,continuous,,30,,30,2,,3,,values given as score (range),FALSE,TRUE,FALSE,FALSE,6401,5359,3891,TEST
694,5636,5712123,postoperative pain on movement,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,continuous,,30,,30,3.5,,3,,values given as score (range),FALSE,TRUE,FALSE,FALSE,6401,5359,3891,TEST
695,5639,5712123,morphine requirements,E group,P group,continuous,,30,,30,,,,,found in fig3,TRUE,FALSE,FALSE,FALSE,6401,5359,3891,TEST
696,5639,5712123,morphine requirements,D group,P group,continuous,,30,,30,,,,,found in fig3,TRUE,FALSE,FALSE,FALSE,6401,5359,3891,TEST
697,5639,5712123,morphine requirements,D/E group,P group,continuous,,30,,30,,,,,found in fig3,TRUE,FALSE,FALSE,FALSE,6401,5359,3891,TEST
698,5637,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Placebo group (P),continuous,,30,,30,,,,,found in fig2,TRUE,FALSE,FALSE,FALSE,6401,5359,3891,TEST
699,5638,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),etoricoxib (E),continuous,,30,,30,,,,,found in fig2,TRUE,FALSE,FALSE,FALSE,6401,5359,3891,TEST